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INTRODUCTION 
 
1.1. Thioredoxin superfamily 
Thioredoxins (Trx) are small globular proteins that are found in all living 
cells from archeabacteria to humans [Holmgren, 1985]. These proteins are 
involved in several biological functions including dithiol hydrogen donation 
in ribonucleotide reduction, structural roles in coliphages such as f1 and 
M13, regulation of the activity of photosynthetic enzymes and some 
eukaryotic transcription regulation factors [Holmgren, 1989; Jacquot et al., 
1994; Holmgren, 1995]. Members of this family contain an active site with 
the CXXC sequence, also known as the “Trx-motif”. The oxidized form of 
the protein is reduced by a NADPH-linked system, present in all types of the 
cells, in which Trx obtains electrons from NADPH via the flavin enzyme 
thioredoxin reductase (TrxR) [Štefanková et al., 2005]. 
 
 
Figure 1. Thioredoxin NADPH-linked system schematic representation. 
 
This system is a general disulfide reductase and catalyzes NADPH-dependent 
reductions of exposed S-S bridges in a variety of proteins [Holmgren, 1985]. 
The 3-D structures of Trx proteins are highly conserved and are characterized 
by a central core, consisting of five β-sheets surrounded by four α-helices 
[Holmgren, 1995; Martin et al., 1995]. This structural configuration is known 
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as thioredoxin fold and is present in different protein families, such as protein 
disulfide isomerases (PDIs), in DSB (disulphide bond formation) proteins, in 
glutaredoxin (Grx), in the glutathione reductase and glutathione peroxidase. 
 
Figure 2. The typical Trx-fold. 
 
The structural features that are conserved in Trx family members, such as the 
Trx-fold and the specific primary and secondary structures, lead to  a 
different reactivity in catalysing protein disulfide interchange reactions. It has 
been shown that both active site cysteine residues play an important role in 
the differentiation of the properties across the family and that the relative 
stability (depending on cysteines nucleophilicity) of thiolates determines 
whether these enzymes catalyze oxidation, reduction or isomerization of thiol 
residues in protein substrates. Following this line, Trx is a good reducing 
agent because its cysteine thiolates are both poorly stabilized; DsbA is a good 
oxidizing agent (it stabilizes both cysteine thiolates) and isomerases like PDI 
have one thiolate (solvent exposed) poorly stabilized and the other (buried) 
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highly stabilized [Cheng et al., 2011; Hatahet et al.,2009; Carvalho et al., 
2009]. 
 
1.2. Protein Disulfide Isomerase family 
The protein disulfide isomerase (PDI) family is composed by 21 known 
proteins in humans that belong to the thioredoxin superfamily, classified by 
sequence and structural homology.  
 
 
Figure 3. PDI family members in humans. In blue: catalytic domains a and a’, in green and 
purple non catalytic b and b’ domains. 
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These enzymes catalyze the formation, reduction or isomerization of 
disulfide bonds of newly synthesized proteins in the lumen of the 
endoplasmic reticulum (ER). They are also part of a quality-control system, 
thanks to their molecular chaperone function. These proteins show a 
structural organization with multiple domains; each domain shows the typical 
Trx-fold and two or three of these domains contain the redox-active -CXXC- 
motif, while the others are considered Trx inactive domains [Turano et al., 
2002]. Thanks to these redox-inactive domains, PDIs have the ability to bind 
peptides or proteins and to exert a molecular chaperone function [Ferrari et 
al., 1999; Ellgaard et al., 2005]. The number, the arrangement of tioredoxin-
like domains and the specific sequence of the catalytic -CXXC- motif can be 
used to differentiate the members of this family. These differences determine 
their respective role in the oxidative folding, but also contribute to their 
specific functions in other pathways. Furthermore, the differences in their 
redox active motifs can reflect separated roles in oxidation, reduction and 
isomerization [Maattanen et al., 2006]. 
 
 
Figure 4. PDIs disulphide bond exchange. Depending on the redox form, they can catalyse 
oxidation, reduction or isomerization. 
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1.3. PDIA3 protein 
PDIA3, encoded by the gene PDIA3 on chromosome 15, is a protein of 505 
amino acids and a molecular weight of 57KDa. It is also known as ERp57, 
ERp60 or GRp58 (glucose-related protein 58). Its structure contains four Trx-
like domains: a and a’ are redox active and contain the active site constituted 
by the tetrapeptide CGHC (cysteine-glycine-histidine-cysteine), while b and 
b’ domains are redox inactive. 
 
Figure 5. Protein PDIA3 modular structure. 
 
PDIA3 modular structure is similar to the one of PDI, but lacks the C-
terminal acidic region. At the amino acid level, similarity is highest in the 
catalytic domains a and a’ (about 50 %) and lowest in the bb’ domains (20%) 
[Kozlov et al., 2006]. The C-terminus contains a gln-glu-asp-leu (QEDL, 
502QEDL505) sequence that is similar to the canonical ER-retention 
sequence (KDEL) and a nuclear localization signal (NLS, 
494KPKKKKK500). Deletion and mutation experiments revealed that NLS 
is fundamental for PDIA3 translocation in the nucleus. Furthermore, both C-
terminal NLS/ER regions are required for ER retention following PDIA3 
targeting to the ER through the hydrophobic N-terminal signal peptide. It has 
been demonstrated that an overlapping NLS/ER retention signal is required 
for nuclear localization and ER retention of PDIA3 [Adikesavan et al., 2008]. 
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The canonical ER retention signal sequence is KDEL, whose binding to 
KDEL receptors ensures retention in the ER, for proteins normally present in 
the ER that have been transported beyond this compartment [Pelham et al., 
1988]. It has been hypothesized that variations between retention sequences 
(e.g. QEDL, KEEL) may influence their cellular sorting and localization 
[Turano et al., 2002]. Protein disulfide isomerase PDIA3 is localized 
predominantly in the ER but is also present in the cytosol, in the nucleus and 
on the cell surface [Adikesavan et al., 2008; Jordan et al., 2006]. 
 
1.3.1.  PDIA3 in the ER 
PDIA3 is mainly located in the ER, where it participates to the correct 
folding and to the quality control of neo-synthesized glycoproteins meant to 
be secreted or localized to the cell membrane. To do this PDIA3 interacts 
with lectins calreticulin (CRT) or calnexin (CNX), which are responsible for 
recognizing and binding to monoglycosylated proteins [Oliver et al., 1997; 
Molinari et al., 1999; Oliver et al., 1999]. It has been reported that 
modifications of specific residues in the b’ domain of PDIA3 reduce or 
abolish its binding to calreticulin, indicating that this domain is responsible 
for the interaction [Russell et al., 2004]. PDIA3, in complex with CRT/CNX, 
performs disulfide shuffling, a process that requires the intermediate 
formation of a mixed disulfide between the glycoprotein and the proximal 
cysteine of one of the two active sites of PDIA3. The shuffling is then 
completed by the intervention of the distal cysteine present in the same active 
site. A second important function of PDIA3 in the ER is the participation in 
the assembly of the major histocompatibility complex (MHC) class I 
[Lindquist e al., 1998]. An efficient antigen processing through the MHC I 
INTRODUCTION  
 
7 
 
requires the formation of the peptide-loading complex (PLC). This complex 
consists of the transporter associated with antigen processing (TAP) as 
centerpiece, which recruits the major histocompatibility complex class I 
(MHC I) heavy-chain/β2-microglobulin dimer by the adapter protein tapasin 
(Tsn). The transient Tsn-MHC I interaction is stabilized by PDIA3, and the 
endoplasmic reticulum (ER) chaperone calreticulin (CRT), which recognizes 
the monoglucose unit of N-core glycosylated MHC I molecules. In the PLC 
PDIA3 interacts with tapasin [Dick et al., 2002]; the structure of this complex 
has been resolved at 2.6 Å resolution [Dong et al., 2009]; this was the first 
time in which the whole 3D structure of PDIA3 was obtained. Both a and a' 
domains of PDIA3 are involved in the interaction with tapasin. The cysteine 
57 in the a domain of PDIA3 forms a disulfide bond with cysteine 95 of 
tapasin, while the a' domain-tapasin interaction is entirely non-covalent. The 
tapasin-PDIA3 complex is essential in the assembly and the stabilization of 
the PLC; PDIA3 shows a structural role rather than a catalytic one. In fact the 
suppression of PDIA3 affects the stability of PLC and decreases both the 
expression of MHC on the cell surface and the peptide loading within the 
PLC [Garbi et al., 2006]. PDIA3 also modulates the activity of 
sarco/endoplasmic reticulum calcium ATPase (SERCA), a Ca
2+
-ATPase that 
transfers Ca
2+
 from the cytosol to the lumen of the ER, by regulating the 
redox state of the sulfhydryl groups in the intraluminal domain of SERCA [Li 
et al., 2004]. 
 
1.3.2. PDIA3 in the cytosol 
PDIA3 has been reported in the cytosol thanks to the interaction with other 
proteins. In this localization it associates with STAT3 [Sehgal, 2003]. STAT3 
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is a member of the STAT (Signal Transducer and Activator of Transcription) 
family. In response to cytokines and growth factors, these proteins are 
phosphorylated by receptor-associated kinases and then form homo- or 
hetero-dimers that translocate to the cell nucleus, where they act as 
transcription activators. STAT3 is activated through phosphorylation of 
tyrosine 705, in response to various cytokines and growth factors including 
interferons, epidermal growth factor and interleukin-6 (IL-6). The binding of 
IL-6 family cytokines to gp130 receptors triggers STAT3 phosphorylation by 
JAK2. Hyperactivation of STAT3 is frequently observed in a variety of 
human cancers, including head and neck cancer [Yu et al.,2004; Yu et al, 
2009; Song et al., 2000]. Continuous STAT3 activation allows the growth 
and survival of cancer cells through modulation of cell cycle regulators (e.g., 
cyclin D1/D2 and c-Myc), upregulation of anti-apoptotic proteins (e.g., Mcl-
1, Bcl-xl, and survivin), downregulation of the tumor suppressor p53, and 
induction of angiogenesis by vascular endothelial growth factor (VEGF); 
these mechanisms lead to tumor progression and resistance to anti-cancer 
drugs [Frank, 2013; Yu et al.,2004; Yu et al, 2009]. It has been reported that 
PDIA3 modulates STAT3 activity [Eufemi et al., 2004; Chichiarelli et al., 
2010], although there are controversial results [Coe et al., 2010].  For 
instance, PDIA3 has been reported to interact with and enhance STAT3 
activity in melanoma and hepatoma cells [Eufemi et al., 2004; Chichiarelli et 
al., 2010], whereas another group suggested that this PDIA3-STAT3 complex 
negatively affects STAT3 DNA-binding activity [Coe et al., 2010]. Hence, 
the role of PDIA3 in the STAT3 activity regulation is still not completely 
defined. 
As a further proof of PDIA3 presence in the cytosol, it was found in 
INTRODUCTION  
 
9 
 
association with mTOR [Ramírez-Rangel et al., 2011]. mTOR is a serine-
threonine protein kinase, found in two multiprotein complexes called 
mTORC1 and mTORC2, which regulate cell proliferation. PDIA3 
contributes to the assembly of mTORC1, activates the kinase activity of 
mTOR, and also participates in the mechanism by which mTORC1 detects its 
upstream signals, such as stimulation by insulin or nutrients. PDIA3 over-
expression induces cellular proliferation, while PDIA3 knockdown opposes 
the proliferation induced by insulin and nutrients. It is reasonable that part of 
this behaviour is related to the mTOR-PDIA3 interaction, considering that 
mTOR is involved in the regulation of proliferation. 
 
1.3.3. PDIA3 in the nucleus 
PDIA3 was found for the first time in the nuclei of 3T3 cells and rat 
spermatids [Ohtani et al., 1993] and of chicken hepatocytes, where PDIA3 
was found mainly in the internal nuclear matrix fraction [Altieri et al., 1993]. 
This observation was at first not easily accepted, because it was considered 
unlikely that a protein provided with an ER retention signal can escape from 
the endoplasmic reticulum. However, nowadays there is ample experimental 
evidence, provided by different laboratories with a variety of experimental 
techniques, that PDIA3 can be found in the nucleus. It has been shown that 
PDIA3 is present in the nuclei of HeLa cells and that it interacts directly with 
DNA [Coppari et al., 2002]. PDIA3 interacts preferentially with A/T rich 
regions, and in general with DNA regions typical of the MARs (nuclear 
matrix associated regions) [Coppari et al., 2002; Ferraro et al., 1999]. The 
DNA fragments immunoprecipitated with an anti-PDIA3 antibody from 
HeLa and Raji cells were enriched in sequences contained either in introns or 
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in 5’-flanking regions of known genes [Chichiarelli et al., 2007; Chichiarelli 
et al., 2010]. This can be compatible with a gene expression regulatory 
function. Furthermore, the consensus sequences for STAT3 were found to be 
associated both with this transcription factor and with PDIA3 [Chichiarelli et 
al., 2010]. Because of the relatively low affinity for DNA and its lack of 
stringent sequence specificity, PDIA3 cannot itself be considered as a 
transcription factor, but it might be considered an accessory protein for 
transcription regulation, possibly maintaining the transcription factors in their 
proper redox state. 
Moreover, PDIA3 shows in vitro DNA-binding properties that are strongly 
dependent on the redox state of the protein. The DNA binds to the a' domain 
[Grillo et al., 2002] and the binding requires the oxidized form of PDIA3 
[Ferraro et al., 1999; Grillo et al, 2007].  Evidences, from M14 melanoma 
cells and HepG2 hepatoma cells, demonstrated the association of STAT3 and 
PDIA3 also in the nucleus at the level of DNA interaction [Eufemi et al., 
2004; Chichiarelli et al., 2010]. The PDIA3 silencing in M14 cells causes a 
decrease in the expression of the STAT3-dependent gene CRP [Chichiarelli 
et al., 2010], suggesting the possibility of a positive involvement of PDIA3 in 
the signalling and/or DNA binding of STAT3.  
In NB4 leukemia cells, PDIA3 and NFkB translocate to the nucleus after 
treatment with calcitriol and phorbol ester [Wu et al., 2010], hypothesizing, 
again, a role of PDIA3 in the control of gene expression through regulation of 
the conformation of associated transcription factors. 
Finally, PDIA3 displays in vitro and in vivo affinity for Ref-1, a protein 
involved in DNA repair as well as in the reduction and activation of 
transcription factors. These two proteins appear to cooperate in the activation 
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of a variety of transcription factors, which need to be in their reduced form in 
order to bind DNA [Grillo et al.,2006].  
 
1.3.4. PDIA3 on cell membrane and secretion  
The first time in which it was observed that PDIA3 can escape from the ER 
was when Hirano et al. noticed that the protein was being secreted from 3T3 
cells [Hirano et al., 1995]. Afterwards several studies showed that PDIA3 
could be found on the cell surface or in complexes with cell membrane 
proteins.  
PDIA3 has been found on the surface of the sperm head, where it is required 
for sperm-egg fusion [Ellerman et al., 2006]. Possibly the PDIA3 role is 
related to the thiol-disulfide exchange reactions necessary for the gamete 
fusion process. 
One of the function of PDIA3 on the cell surface is the binding of the 
hydroxylated, hormonal form of vitamin D3, i.e. 1α,25-
dihydroxycholecalciferol (1α,25-(OH)2D3, calcitriol) [Nemere et al., 2004], 
followed by activation of non-genomic responses and the internalization and 
nuclear import of PDIA3 itself.  
It has been demonstrated that PDIA3 exists in caveolae, where it interacts 
with phospholipase A2 (PLA2) activating protein (PLAA) and caveolin-1 to 
initiate a rapid signalling in musculoskeletal cells via PLA2, phospholipase C 
(PLC), protein kinase C (PKC) and the ERK1/2 family of mitogen activated 
protein kinases (MAPK) [Boyan et al., 2012]. 
Moreover it was recently reported that PDIA3 is associated and co-localizes 
with β-DG (one of the two subunit of the extracellular receptor dystroglycan, 
DG) at the plasma membrane of 293-Ebna cells. It has been argued that 
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PDIA3 may assist DG during its post-translational maturation or that it could 
modulate DG redox state [Sciandra et al., 2012]. 
PDIA3 is also present on the platelet surface and it has been showed that its 
inhibition blocks platelet activation [Holbrook et al., 2012; Wu et al., 2012]. 
PDIA3 is secreted by platelets and endothelial cells upon vascular injury and 
accumulates in the thrombus, where it regulates the activation and 
recruitment of other platelets [Holbrook et al., 2012]. 
Dihazi et al. [Dihazi et al.,2011] showed that PDIA3 was found to be secreted 
by renal cells in high amounts upon profibrotic cytokine treatment, and to 
interact with extracellular matrix (ECM) proteins, such as fibronectin and 
collagen. These data suggest that secreted PDIA3 could participate in ECM 
synthesis and stabilization, thus potentially leading to a progressive renal 
fibrosis. 
 
1.4. PDIA3 and diseases 
PDIA3 has been associated with several human diseases such as cancer, prion 
disorders, Alzheimer’s disease, Parkinson’s disease and hepatitis [Hetz et al., 
2005; Martin et al., 1993; Muhlenkamp and Gill, 1998; Seliger et al., 2001; 
Erickson et al., 2005; Tourkova et al., 2005]. PDIA3 expression is increased 
in transformed cells, and it is thought that its role in oncogenic 
transformation is directly due to its ability to control intracellular and 
extracellular redox activities [Hirano et al., 1995]. An increase in PDIA3 
expression has also been observed in the early stages of prion disease, 
suggesting that it may play a neuroprotective role in the cellular response to 
prion infection [Hetz et al., 2005]. Parkinson’s disease is characterized by the 
progressive loss of dopaminergic neurons of the substantia nigra. It has been 
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shown that the treatment of cell lines with 6-hydroxidopamine (6-OHDA, a 
Parkinson mimetic neurotoxin that selectively kills dopaminergic neurons) 
induces PDIA3 oxidation and PDIA3-DNA conjugates formation. It was 
suggested that PDIA3 plays an early adaptive response in toxin-mediated 
stress [Kim-Han et al., 2007]. 
 
1.4.1. PDIA3 and Alzheimer’s disease 
 Alzheimer’s disease (AD) is a common neurodegenerative disorder in 
humans, characterized by deposition in the brain of β amyloid (Aβ) plaques 
and neurofibrillary tangles (NFTs). Aβ plaques are constituted by Aβ1-40 
and Aβ1-42 peptides, which are the results of the APP (amyloid precursor 
protein) proteolytic cleavage and are thought to be the main cause of the 
Alzheimer development [Blennow et al., 2006; Ling et al., 2003]. It has been 
found that Aβ is present in Alzheimer’s patients plaques only as a naked 
peptide, while it is complexed to PDIA3 and calreticulin in the cerebrospinal 
fluid (CSF) of healthy individuals; it was postulated that normally PDIA3 
and calreticulin bind to N-glycosylated Aβ in order to keep it in solution 
preventing its aggregation and deposition. [Erickson et al., 2005].  
It is now widely known that plaque formation is due to the failure of the ER 
post translational processing of APP [Holtzman et al., 2013]; this condition is 
also a typical manifestation of aging. In this regard it was found a decrease in 
PDIA3 levels with age [Erickson et al., 2006] and in N-glycosylated proteins 
in the tissue of the elderly [Kousvelari et al., 1988]. These findings may give 
an explanation of what happens in Alzheimer’s disease: the decrease in 
PDIA3 levels could impair its ability to keep Aβ in solution, even more if Aβ 
is not glycosylated due to the reduced cell ability to produce N-glycosylated 
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proteins. Tohda et al. reported the beneficial effect of diosgenin on the 
memory deficit in an AD mice model and on retrieval of axonal and 
presynaptic degeneration in the cerebral cortex and hippocampus, detecting 
PDIA3 as a target of diosgenin. Interestingly they showed that diosgenin-
induced axonal growth was significantly inhibited in primary cortical neurons 
after PDIA3 knockdown [Tohda et al., 2012]. 
 
1.5. ER stress and UPR 
The endoplasmic reticulum (ER) is a multifunctional cellular organelle 
responsible for several functions necessary for cell survival, such as folding, 
post-translational modification, transportation, and quality control of newly 
synthesized proteins. Endogenous or exogenous insults can alter ER 
functions through disruption of calcium and redox homeostasis, glucose 
starvation and protein misfolding. The result of these alterations is the 
induction of ER stress [Paschen and Frandsen, 2001; Schroder and Kaufman, 
2005; Rao et al., 2004; Breckenridge et al., 2003]. ER stress results in 
activation of the unfolded protein response (UPR) with the aim to alleviate 
the stress and to restore the proteostasis. In order to do that, the UPR causes 
changes in the expression of a huge amount of genes; for instance it causes 
general translational attenuation, reducing the load of proteins within the ER, 
and up-regulation of protein chaperones, promoting protein folding, in order 
to maintain the quality control of proteins while the misfolded proteins get 
degraded through ER-associated degradation (ERAD) and autophagy. 
However, in circumstances of chronic or prolonged ER stress, the UPR 
activates apoptotic signalling, therefore triggering cell death. The UPR is 
mediated by three ER stress sensors: PKR-like endoplasmic reticulum kinase 
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(PERK), inositol-requiring kinase 1 (IRE1), and activating transcription 
factor 6 (ATF6). These sensors induce UPR after the recognition of ER 
stress/misfolding of proteins. Under normal conditions, these ER stress 
sensors are bound to the ER chaperone BiP (or GRP-78, glucose-related 
protein 78), which keeps them in an inactivated state. In presence of ER 
stress, which leads to  accumulation of misfolded proteins in the ER lumen, 
BiP dissociates from the ER stress sensors to preferentially bind the 
hydrophobic regions of the misfolded proteins, thus resulting in sensors’ 
activation (Fig. 6) [Rutkowski et al., 2006].  
  
Figure 6. A schematic demonstrating the action of the three ER stress sensors on the 
Unfolded Protein Response. [Mahdi et al., 2016] 
 
Once activated, PERK phosphorylates, and thus inhibits, the ubiquitous 
eukaryotic translation initiation factor 2α (eIF2α). In this way there is a 
decrease in the number of newly synthesized proteins into the ER lumen, 
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therefore reducing the load of ER protein-folding [Boyce et al., 2005]. 
Phosphorylation of eIF2α also brings to the translation of the mRNA 
encoding ATF4. This transcription factor translocates to the nucleus where it 
induces the expression of ER chaperones to increase refolding of misfolded 
proteins [Halperin et al., 2014]. ATF4 also induces the expression of various 
genes involved in autophagy, antioxidant response, amino acid biosynthesis 
and transport [Cao and Kaufman, 2012; Hetz and Mollereau, 2014]. Under 
ER stress, ATF6 is activated and then translocates from the ER membrane to 
the Golgi apparatus where it is cleaved by site-1 and site-2 proteases. The 
resulting cleaved ATF6 translocates from the cytosol to the nucleus where it 
induces transcription of ER chaperones, ERAD components and XBP-1 
[Schröder and Kaufman, 2005].  
 
1.5.1.  IRE1 
The UPR mediator IRE1 is a transmembrane receptor kinase located on the 
surface of the endoplasmic reticulum (ER). This protein consists of different 
domains: the luminal domain, the transmembrane domain (TM), the linker 
domain, the kinase domain and the endoribonuclease domain (KEN) (Fig. 7) .  
 
Figure 7. Schematic representation of human IRE1. Luminal domain, transmembrane 
domain (“TM”), linker domain, serine/threonine kinase domain (S/T kinase), and 
endoribonuclease domain (RNase). [Kaufman et al., 2002] 
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When ER stress occurs, BIP dissociates from the luminal domain of IRE1; 
interactions of the stress-sensing luminal domains of two IRE1 monomers 
[Bertolotti et al., 2000; Credle et al., 2005; Kimata et al., 2007] promotes 
trans-autophosphorylation of the kinase and RNase domains on the 
cytoplasmic side of the ER membrane [Ali et al., 2011; Shamu and Walter, 
1996]. Phosphorylation allows the binding of  nucleotides in a pocket present 
in the kinase domain. Nucleotide binding triggers conformational changes in 
IRE1, which stabilize the dimer. This rearrangement in the RNase domain 
places the residues necessary for the catalysis in the correct orientation 
[Korennykh et al., 2011]. It is also known that IRE1 can arrange in higher-
order oligomers [Korennykh et al., 2009; Li et al., 2010]. 
 
Figure 8. Schematic representation of IRE1 signalling pathway. [Coelho and 
Domingos, 2014] 
 
The active endoribonuclease (RNase) domain of IRE1 cleaves a 26 
nucleotide intron of the mRNA coding for the transcription factor XBP1 ( X-
box binding protein-1) in mammalian cells [Calfon et al., 2002; Gonzalez et 
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al., 1999; Kawahara et al., 1997; Sidrauski and Walter, 1997]. The resulting 
cleaved exons are then ligated by the RNA ligase RtcB [Lu et al., 2014] in 
order to obtain the spliced form of the XBP1 mRNA. This potent 
transcription factor  regulates the expression of several genes important for 
the re-establishment of ER functions; among these there are genes encoding 
ER-resident molecular chaperones [Lee et al., 2003] and components of the 
ERAD (ER-associated protein degradation) machinery [Oda et al., 2006; 
Yoshida et al., 2003]. Activated IRE1 can also cleave a subset of mRNAs 
encoding proteins targeted to the ER [Han et al., 2009; Hollien et al., 2009; 
Hollien and Weissman, 2006; Kimmig et al., 2012; Mishiba et al., 2013] In 
this case the cleavage leads to mRNA degradation; this process has been 
called regulated IRE1-dependent decay (RIDD) [Hollien et al., 2009]. RIDD 
regulates many physiological processes, including degradation of mRNAs 
encoding a subset of ER or secretory proteins prone to misfolding [Hollien 
and Weissman, 2006; Han et al., 2009; Hollien et al., 2009; Oikawa et al., 
2010], regulation of lipid metabolism genes [So et al., 2012] and fatty acid 
transport proteins [Coelho et al., 2013]. RIDD is also responsible for the 
degradation of several miRNAs’ precursors, such as miR-17, miR-34a, miR-
96, and miR-125b with consequent translation of TXNIP (thioredoxin 
interacting protein) and caspase-2 mRNAs [Lerner et al., 2012; Oslowski et 
al., 2012; Upton et al., 2012]. TXNIP causes activation of caspase-1 and 
secretion of interleukin 1β, leading to apoptosis [Lerner et al., 2012]. The role 
of caspase-2 in ER stress-induced apoptosis has been questioned; indeed a 
report claimed that ER stress did not cause upregulation and activation of 
caspase-2 [Sandow et al., 2014]. Moreover IRE1, through its kinase domain, 
activates the c-Jun N-terminal kinases (JNKs) via the formation of a complex 
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with the E3 ubiquitin ligase TRAF2 (TNF receptor-associated factor 2) and 
the apoptosis signal regulating kinase 1 (ASK1), leading to apoptosis. [Urano 
F et al., 2000; Nishitoh H et al., 2002]. IRE1 is not only involved in the 
attempt to restore ER homeostasis under stress conditions but it also essential 
for physiological processes requiring high levels of secretion, such as the 
differentiation of B cells in plasma cells [Zhang et al., 2005] and insulin 
secretion from pancreatic beta cells. It has been demonstrated in several 
studies that alteration in IRE1 function occurs in different diseases such as 
cancer, diabetes, inflammatory and neurodegenerative diseases [Hetz  and 
Glimcher, 2011; Hetz et al., 2011]. 
It still not entirely known how IRE1 regulates cell fate; in particular, which 
of IRE1 activities are associated to cell survival and which to cell death.  It 
has been shown that amplitude and duration of its activation plays an 
important role [Hetz, 2012]. The common thinking is that XBP1 splicing has 
mostly a prosurvival effect; in fact, it has been observed that high levels of 
XBP-1(S) increase tumor cell survival [Davies MP et al., 2008], whereas 
RIDD shows a proapoptotic output that dominates in other diseases, such as 
diabetes [Hetz  and Glimcher, 2011; Hetz et al., 2011]. Nevertheless, the 
precise mechanisms of these actions need to be further investigated.  
 
1.6. Flavonoids  
Flavonoids are a large class of plant secondary metabolites present in fruits, 
vegetables and plant-based beverages such as tea and red wine [Pérez-
Jiménez et al., 2010]. These polyphenolic compounds are classified into 
flavones, flavonols, iosflavones, flavanones, flavanols and anthocyanidins 
[Manach et al., 2004; Bravo, 1998] (Fig. 9).  
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Figure 9. Flavonoid structures and occurrence. Arrows indicate biosynthetic path. 
 
Flavonoids show multiple health beneficial effects; many studies have 
suggested an association between consumption of flavonoids-rich food or 
beverages and the prevention of many degenerative diseases, including 
cancer, neurodegeneration and coronary heart disease and stroke [Woo et al., 
2013; Neuhouser, 2004; Hui et al., 2013; Aune et al., 2012; Hertog et al., 
1993]. The protection offered by flavonoids is believed to be due to their 
antioxidant activity. The aromatic rings of the flavonoid molecule allow the 
donation and acceptance of electrons from free radical species [Halliwell, 
2006]. It has been suggested that, in lower amounts, flavonoids may exert 
pharmacological activity within the cells, although for most of them the 
cellular basis of these activities is not well known. By affecting different 
pathways, such as cell signalling, cell cycle, free radical scavenging, 
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angiogenesis, DNA repair mechanisms and apoptosis, flavonoids have the 
ability to control cell proliferation and survival, and to exhibit 
antiproliferative and antimutagenic properties and a remarkable anti-
inflammatory activity [George et al., 2016; Jayasena et al., 2013; Mandel et 
al., 2011;Vauzour et al., 2010]. 
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2. AIMS OF THE RESEARCH 
AIM 1: to perform a wide screening study to identify specific flavonoid 
molecules that bind and modulate PDIA3 activity, useful to regulate the 
cellular processes and signalling pathways involving PDIA3. 
PDIA3 is a multifunctional protein disulfide isomerase with a wide range of 
functions. It has been shown that this protein is involved in the cellular 
response to stress as well as in cancer and neurodegeneration. Flavonoids 
displays a wide range of biological effects, such as antioxidant, anti-
inflammatory, antithrombotic, antiviral and antitumor activities. However, 
for many of them the molecular and cellular bases of these activities are not 
well known. Flavonoids can act on different targets affecting regulation of a 
variety of pathways: cell signalling and cell cycle, free radical scavenging, 
inhibition of angiogenesis, initiation of DNA repair mechanisms, apoptotic 
induction and inhibition of metastasis. Starting from previous work done in 
our lab, which showed that green tea catechins are able to modify PDIA3 
activity [Trnkova et al., 2013], we expanded this study to various classes of 
flavonoids and performed a wide screening study for assessing the interaction 
and impact on PDIA3 protein activity of several types of flavonoids. Our 
hypothesis is that some of the flavonoids’ activities are connected to the 
modulation of PDIA3 functions. The binding of several flavonoids to PDIA3 
and their effects on the protein were tested by protein fluorescence 
quenching. PDIA3 redox and DNA-binding activities were also analyzed in 
the presence of flavonoids.  
AIM 2: to study PDIA3 implications in Alzheimer’s disease (AD) and β-
amyloid deposits.  
Evidences from the literature suggest that PDIA3 might have a role in AD 
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pathogenesis [Erickson et al., 2005; Tohda et al., 2012], but its exact 
contribution is not clear. In order to shed light on this interesting question, we 
mimicked AD pathological conditions by treating a neuronal cell model with 
β-amyloid peptide and analyzed PDIA3 role in AD. In particular we 
investigated PDIA3 expression levels through western blot and qRT-PCR 
analysis, PDIA3 localization by means of immunofluorescence studies and 
PDIA3 secretion before and after β-amyloid peptide treatment. 
AIM 3: to understand how different IRE1 activities are related to each 
other, to cell fate under ER stress and to IRE1 protein dimerization and 
oligomerization. 
The last part of my PhD program was performed at The Children’s Hospital 
of Philadelphia, where I worked under doctor Yair Argon’s supervision on 
the UPR sensor and mediator IRE1, a serine threonine protein kinase that 
possess endonuclease activity. IRE1 is an ER transmembrane protein 
essential for developmental processes requiring high levels of secretion, such 
as the differentiation of plasma cells and pancreatic beta cells.  Under normal 
conditions IRE1 is present as an inactive monomer bound to the chaperone 
BIP. In response to ER stress, BIP dissociates from IRE1, with consequent 
IRE1 activation, which consists in dimerization, trans-autophosphorylation, 
conformational changes and activation of the RNase domain, which affects 
downstream targets to work as an administrator of cell fate under ER stress.  
Following activation, IRE1 has three main activities: XBP1 mRNA splicing; 
specific mRNAs and miRNAs degradation (RIDD, regulated IRE1 dependent 
decay) and activation of the JNK pathway through TRAF2 interaction. 
Together, these activities are responsible for both adaptive responses and 
apoptosis, but nobody has ever separated each outcome. 
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It is known that IRE1 can exist in a monomeric state (inactive) or after 
activation in dimeric and oligomeric (clustering) states. The differences and 
the functions of these last IRE1 states are still not known and different 
researchers have only postulated their activities. Our hypothesis is that IRE1 
clustering is related to two activities of IRE1: RIDD and activation of the 
JNK-pathway, which are commonly believed to have a pro-apoptotic 
outcome following ER stress, but not to XBP1 mRNA splicing, which 
activates pro-survival responses. To investigate this aspect we used an IRE1 
knock-out cell line, recomplemented with a recombinant GFP-tagged human 
IRE1, either as wild type version or containing several point mutations. Our 
goal was to find IRE1 mutant proteins that can perform one activity but not 
the other ones to allow us to connect the different outcomes to each activity. 
In this part we focused our attention mainly on XBP1 splicing and clustering, 
leaving the study of RIDD and JNK pathway activation for further studies. 
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3. MATERIALS AND METHODS 
 
3.1. Reagents  
PBS solution, acrylamide, N-ethylmaleimide, DTT, GSSG, eosin 
isothiocyanate and different flavonoids (quercetin, 3-O-methyl-quercetin, 
isoquercetin, quercitrin, rutin, morin, rhamnetin, isorhamnetin, fisetin, 
apigenin, apigenin-7-glucoside, luteolin-7-glucoside, kaempferol, eupatorin, 
eupatorin-5-methyl-ether, genistein, narigenin, cyanidin and 6,2’,4’-
trimethoxyflavone), cycloheximide, brefeldin A, doxycycline hydrochloride 
and MG-132 were from Sigma-Aldrich; thapsigargin and tunicamycin from 
Calbiochem; EDTA (0.5 M solution pH 8.0) from IBI Scientific. Amyloid 
beta peptide 25–35 fragment (Aβ25–35), synthesized by conventional solid 
phase chemistry [Atherton and Sheppard, 1989], was aggregated overnight at 
37°C in phosphate buffered saline at a concentration of 1mM. 
 
3.2. Protein expression and purification 
Human recombinant PDIA3 was cloned and expressed in E. coli strain BL21 
using the expression vector pET21 (Novagen) as previously described 
[Coppari et al., 2002]. The coding sequence for the second redox-active 
domain (a’ domain, residues 377-505) was amplified by PCR as previously 
described and cloned in the expression vector pET29 (Novagen) [Grillo et al., 
2007]. Recombinant proteins were expressed in E. coli strain BL21 and 
purified by ammonium sulphate fractionation, ion exchange and heparin 
chromatography [Grillo et al., 2006; Grillo et al., 2007]. Protein purification 
was evaluated by SDS-PAGE and concentration was determined 
spectrophotometrically (PDIA3 Ɛ280 reduced form = 44,810 M-1cm-1, a’ 
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domain Ɛ280 reduced form =14,400 M-1cm-1). 
 
3.3. Fluorescence Quenching Measurements 
Quantitative analysis of the interaction between individual flavonoids and 
PDIA3 was performed by fluorimetric titration. Fluorescence spectra were 
recorded using a SPEX-FluoroMax spectrofluorimeter (Horiba Scientific) 
from 300 to 500 nm with excitation at 290 nm using a 10 mm path length 
quartz fluorescence cuvette and under continuous stirring. The excitation and 
emission slits were both set to 5 nm and scan speed was 120 nm·min-1. 
Briefly, solution of PDIA3 (0.5 μM) or a’ domain (1 µM) in phosphate 
buffered saline (PBS) containing DTT 0.1 mM and EDTA 0.2 mM were 
titrated in quartz cuvette by stepwise additions, at 5 min time intervals, of 
individual flavonoid solution (1 mM in PBS/ethanol 50:50 v/v freshly 
prepared from a 20 mM stock solution in DMSO). Most of tested flavonoids 
can absorb light at the excitation and emission wavelengths. To minimize the 
inner-filter effect we limited the highest concentration reached in the titration 
test up to 10 µM. All experiments were carried out at 25°C. Each spectrum 
was the mean of three repeated scans. Fluorescence spectra of appropriate 
blanks (flavonoids without proteins) were recorded under the same 
experimental conditions and subtracted from the corresponding flavonoid-
protein system to correct the fluorescence background. Fluorescence 
intensities recorded at 338 nm were used for quenching analysis and data 
obtained for each flavonoid are the average of at least three independent 
titration experiments.  
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3.4. Determination of Protein Disulfide Reductase Activity 
Disulfide reductase activity of PDIA3 was monitored by sensitive fluorescent 
assay using dieosin glutathione disulfide (DiE-GSSG) as fluorogenic probe 
[Raturi A and Mutus B, 2007]. DiE-GSSG was synthesized by the reaction of 
eosin isothiocyanate with oxidized glutathione (GSSG) according to the 
method of Raturi and Mutus [Raturi A and Mutus B, 2007] with some 
modifications [Trnkova et al., 2013]. DiE-GSSG concentration was 
determined spectrophotometrically (Ɛ525 = 88,000 M-1cm-1). Disulfide 
reductase activity was assayed in a reaction buffer containing 2 mM EDTA, 
150 nM DiE-GSSG and 5 µM DTT in PBS. A 20 µl aliquot of a stock 
solution of PDIA3 (1µM) was added to the reaction mixture and DiE-GSSG 
reduction was monitored at 545 nm with excitation at 520 nm, at 25°C with 
continuous stirring. Reductase activity was calculated as the initial velocity in 
fluorescence increase. To test the effect of flavonoids on PDIA3 activity, the 
protein stock solution was previously incubated for 15 minutes at room 
temperature with different concentrations of each flavonoid and then a 20 µl 
aliquot subjected to assay in a reaction buffer containing the same 
concentration of the flavonoid.  
 
3.5. Determination of DNA Binding Activity by EMSA 
EMSA assay was performed using a 79-bp rich DNA fragment obtained by 
PCR as previously described [Grillo et al., 2002]. Amplified DNA was end-
labeled by using 5-florescein-modified primers. 10 ng of DNA fragment was 
incubated with 1 μg of PDIA3 or a’ domain, in presence of increasing 
concentration of flavonoids (from 0 to 50 μM). Controls were performed 
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using DNA alone and in the presence of each flavonoid. All tests were 
performed in 20 μl mixtures containing 20 mM Tris-HCl, pH 7.5, 50 mM 
NaCl, and 10 % (v/v) glycerol. Samples were incubated for 1 hour at 25º C 
and then resolved on 5% polyacrylamide gels in 0,25% TBE buffer (22.5 mM 
Tris-borate, 5 mM EDTA, pH 8.3) at 150 V. Gel images were recorded using 
a ChemiDoc MP Imaging System (BioRad) equipped with an epi-blu 
excitation lamp and a 520nm emission filter. 
 
3.6. Statistical analysis 
Fluorescence quenching constant (KSV) values were given as means ± 
standard deviation and values of disulfide reductase activity were expressed 
in % of control sample ± relative standard deviation. All measurements were 
performed at least three times. Dunnett’s test was used to compare the 
obtained reductase activity data with the activity of the untreated protein and 
a p-value of < 0.01 was considered as statistically significant. 
 
3.7. Cell cultures 
SH-SY5Y cells were grown in Ham’s F12/DMEM; HAP1 cell line was 
grown in IMDM; 293T cells were grown in DMEM. All the media were 
supplemented with 10% FBS (fetal bovine serum), 100 units/ml penicillin, 
100 g/ml streptomycin, 1mM sodium pyruvate, 2mM glutamine. All cells 
were grown to 70-80% confluence at 37° C with 5% CO2.  
 
3.8. Cell lysate preparation 
Adherent cells were washed and scraped with cold PSB. Then, they were 
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harvested by centrifugation and suspended in lysis buffer (50mM Tris pH 
8.0, 150mM NaCl, 20mM iodoacetamide, 5mM KCl, 5mM MgCl2, 1% NP-
40) supplemented with protease and phosphatase inhibitor cocktails 
(PhosSTOP™ from Roche). After centrifugation (15min, 20.000g, 4°C), the 
total protein extracted were quantify using Pierce™ BCA Protein Assay Kit 
(Thermo Fisher Scientific), and resuspended in 1X Laemmli Buffer ( 2% 
SDS, 62,5 mM Tris-HCl pH 6.8, 10% v/v glycerol, 5 mM DTT, 0.02% 
bromophenol blue) for the electrophoresis. 
 
3.9. Proteins precipitation in culture medium 
After growing SH-SY5Y cells on 6-wells plates, the media was taken, 
subjected to 5,000 rpm for 5 minutes to remove cells and the supernatant was 
treated with 0.025% sodium deoxycholate, 10% trichloroacetic acid (TCA) 
over night at 4° C. The day after samples were centrifuged at 10,000 rpm for 
15 minutes at 4° C , a wash in 100 μl of acetone was performed, 10,000 rpm 
for 15 minutes at 4° C centrifugation and air dried. The pellets were 
resuspended in Laemmli buffer 1X. 
 
3.10. Western blot 
Samples in 1X Laemmli buffer were boiled for 5 minutes. Immunoblotting 
was performed using the PPDS module of the Owl Separation System™ 
(Thermo) and 10% 37.5:1 Acrylamide/Bis-Acrylamide poly-acrylamide gels. 
SDS-PAGE was performed using Tris-Glycine-SDS buffer and transferred 
onto 0.45um nitrocellulose membrane (Biorad) in Tris-Glycine buffer plus 
20% methanol, using a Genie™ Blot Module (Thermo). Nitrocellulose 
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membranes were blocked in 5% non-fat milk in TBS buffer. The blots were 
then incubated overnight at 4°C, in 1% non-fat milk/TBS-0.1% Tween (TBS-
T) plus the primary antibody. Afterward the membranes were washed in 
TBS-T and incubated with the appropriate infrared (IR) labeled secondary 
antibody (Licor) in 5% milk/TBS-T. The membranes were washed and 
scanned using the Odyssey® Infrared Imaging System (Licor). Protein bands 
were visualized and densitometry determined by Image J software.  
Rabbit anti-IRE1 (14C10) was purchased from Cell Signaling Technology. 
Rabbit anti-phospho Ser 724 IRE1 was purchased from Novus Biologicals. 
Rabbit anti-PDIA3 was purchased from Millipore. Mouse anti β-actin was 
purchased from Sigma-Aldrich. Mouse anti-BiP antibody was purchased 
from BD Transduction Laboratories. IR secondary antibodies (used at 
1:10000 dilutions) were from Licor. 
 
3.11. Cell viability assay 
Cellular proliferation was examined employing an XTT-based colorimetric 
assay according to the manufacturer’s protocol. Briefly, each of the cells was 
cultured in 96-well plates. After incubation periods of 24 hours, a XTT Cell 
Viability Assay Kit (Biotium) was added to each well and incubation was 
continued for 4 hours at 37°C. Optical density was measured at a wavelength 
of 450 nm using a 96-multiwell microplate reader (BioTek). 
 
3.12. Immunofluorescence 
Cells were grown on glass coverslips (in 6-wells plates, 200,000 cells/well in 
2ml of medium) and the day after they were treated with Aβ peptide for 24 
hours. Afterwards cells were fixed with 4% formaldehyde for 20 minutes, 
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washed 3 times in PBS, permeabilized with 0.2% Triton X-100 for 15 
minutes, washed 3 times with PBS and blocked with 1% w/v BSA (bovine 
serum albumin) over night at 4° C. Immunostaining was performed 
incubating cells with anti-PDIA3 antibody (1:100) for 1 hour, washing 3 
times in PBS, incubating with TRITC-conjugated secondary antibody (1:200) 
(Amersham), then washing again 3 times in PBS. Nuclei were stained with 
DAPI 50 ng/ml for 10 minutes. After washing with PBS, glass microscope 
slides, mounted with ProLong® Gold Antifade Reagent (Invitrogen), were 
examined by fluorescence microscopy. 
 
3.13. Mutagenesis, lentiviral production and infection 
IRE1-sfGFP was previously cloned in pLVX-Tight-Puro vector by PCR in 
Yair Argon’s lab. Site-directed mutagenesis was performed using the 
QuikChange II Site-Directed Mutagenesis Kit (Agilent) to generate the 
following IRE1-GFP mutants: D123P - K907A - L827P. To generate viral 
particles carrying the expression plasmids, 293T cells were co-transfected 
with a mix of packaging plasmids (Invitrogen) and DNA of interest using 
Lipofectamine 2000 (Life Technologies). The next day, the medium was 
replaced with fresh medium. After 24 hours the supernatant was collected 
and subjected to a low-speed centrifugation step to remove any remaining 
cellular debris. Following  filtration with a 0.45 μm filter, the lentiviral 
particles were concentrated with Amicon Ultra-15 10K filters (Millipore). 
Lentiviral titration was conducted as described in ViraPower™ Lentiviral 
Expression Systems User Manual (Invitrogen). IRE1-complemented IRE1-/- 
HAP1s were generated by two consecutive transductions with lentiviral 
particles carrying pLVX-Tet-On™ or pLVX-Tight-Puro™ plasmids 
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(Clontech) at a multiplicity of infection (MOI) = 1. When required, the 
following antibiotics were used to select stable cell clones: 2 μg/mL 
puromycin (Invivogen), 1 mg/mL G418 (Gemini). Pools of transfectants 
were then induced with 1μg/mL doxycycline to express IRE1-GFP or its 
mutants.  
 
3.14. Knockdown of PDIA3  
The viral-based RNAi was conducted with PDIA3 shRNA and shRNA 
control vector clones were from the Mission shRNA library (Sigma). 293T 
were cultured in 6-well plates and transduced with lentiviral particles 
encoding the shRNA sequences, packaged using the VeraPower kit 
(Invitrogen). After 24 h the cells were selected with puromycin as above. 
 
3.15. Total RNA extraction, and Reverse Transcription-PCR 
Cells were harvested and total RNA was isolated with TRIzol® Reagent 
(Invitrogen) following the manufacturer’s instructions. RNA was precipitated 
by adding isopropanol and subsequently centrifuged at 12,500 g for 10 
minutes at 4° C. The precipitated RNA was washed with 75% ethanol and air 
dried. Total RNA was then resuspended in RNase-free water and quantified 
using Thermo Scientific NanoDrop 2000. Purified RNA was subjected to 
reverse transcription using Superscript® First Strand Synthesis System  for 
RT-PCR (Invitrogen), according to manufacturer’s instructions. 
 
3.16. Real-time PCR 
qRT-PCR was performed starting from cDNA  using SYBR® Select Master 
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Mix (Applied Biosystems), according to manufacturer’s instructions and 
through StepOnePlus™ Real-Time PCR System (Applied Biosystems). 
Genes’ expression was evaluated using the following primers:  
PDIA3: forward: GCCACAGTCTTGTCCTCAAACTTG;                                                                                                  
reverse: TTCCTAAAAGCAGCCAGCAACTTG. 
CHOP: forward: GGAGCTGGAAGCCTGGTATG;                                             
reverse: AAGCAGGGTCAAGAGTGGTG 
XBP1 spliced: forward: CTGAGTCCGCAGCAGGTG;                                
reverse: GACCTCTGGGAGTTCCTCCA 
β-actin: forward: GCGAGAAGATGACCCAGATC;                             
reverse: GGA TAGCACAGCCTGGATAG.   
 
3.17. XBP1 splicing assay 
Cells were lysed and total RNA was collected. PolyA mRNA was reverse 
transcribed using the SuperScript-RT system (Invitrogen). cDNA was used as 
template for PCR amplification across the fragment of the Xbp-1 cDNA 
bearing the intron target of IRE1α ribonuclease activity. The primers used for 
the PCR are the following:  
Fwd: AAACAGAGTAGCAGCTCAGACTGC 
Rev: TCCTTCTGGGTAGACCTCTGGGAG 
PCR products, resolved on a 3% agarose/1×TAE gel, consist of three 
amplicons corresponding to unspliced (474 nucleotides) and spliced XBP1 
(474 nucleotides), and a hybrid product consisting of unspliced XBP-1 
annealed to spliced XBP-1. This hybrid species was also produced through 
MATERIALS AND METHODS  
 
34 
 
the PCR and was visible as a slower migrating band above the unspliced 
amplicon. Ethidium bromide (Sigma) stained amplicons were quantified by 
densitometry using ImageJ software (NIH). 
 
3.18. Live Cell Imaging 
IRE1-complemented IRE1 KO HAP1 cells were seed two days before 
imaging onto glass-bottom microwell dishes (MatTek) at 1x10
5
 cells/dish. 
Doxycyline containing medium was added for 24 h, withdrawn before 
imaging and replaced with IMDM media without phenol red. Images were 
acquired with a 63X NA oil objective on a fluorescence inverted microscope 
equipped with a 37°C environmental chamber. 
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4. RESULTS AND DISCUSSIONS 
4.1 Comparative analysis of the interaction between different flavonoids 
and PDIA3 
4.1.1 Flavones eupatorin and eupatorin-5-methyl ether bind PDIA3 
with high affinity 
We started a screening analysis to find molecules that can specifically bind 
PDIA3 and inhibit its redox activity. A number of flavonoids, comprehending 
flavones, flavonols and several derivates, which differ in terms of skeleton 
structure as well as hydroxyl-, methoxyl- and other substituted groups, were 
analyzed (Fig. 10).   
 
Figure 10. Molecular structures of tested flavonoids. 
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The interaction between PDIA3 and these flavonoids was investigated by 
quenching analysis of PDIA3 intrinsic fluorescence. PDIA3 fluorescence is 
mainly due to the presence of three tryptophan residues: one (W279) is 
buried in a hydrophobic pocket in the b´ domain whereas the other two (W56 
and W405) are present on the protein surface close to the thioredoxin-like 
active sites within a and a’ domains, respectively.  
 
Figure 11. (A) Fluorescence quenching spectra of reduced PDIA3 alone (solid line) and after 
stepwise addition of Eupatorin (dotted line) (pH 7.4, 25°C, and λex = 290 nm,). [PDIA3] = 
0.5 x 10
-6
 M, [eupatorin] = 2 x 10
-5
 M final concentration. (B) Stern-Volmer plot of 
quenching data as mean of at least three independent experiments (standard deviations were 
better than 10% and correlation coefficient were better than 0.99). 
 
Quenching analysis was performed on PDIA3 (0.5 µM) in the reduced form, 
by adding stepwise increasing concentration of each molecule and recording 
the protein fluorescence spectra. For some flavonoids the analysis was 
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extended to isolate a’ domain (1 µM), always in the reduced form. Quenching 
effect on protein as well as Stern-Volmer quenching contants (KSV) were 
calculated from the fluorescence intensities at 338 nm of protein alone (F0) 
and in the presence of increasing concentration of each ligand molecule (F) 
using the Stern-Volmer equation [Lakowicz, 2006]:  
F0/F = 1 + KSV[L]    
where L is the ligand concentration. For each ligand molecule the Stern-
Volmer quenching constant was obtained by linear regression of plots of F0/F 
versus [L]. Representative fluorescence spectrum of PDIA3 in the presence 
of increasing concentration of eupatorin is showed in figure 11a. 
Fluorescence quenching data were analyzed using the Stern-Volmer equation. 
The Stern-Volmer plot for PDIA3, in presence of eupatorin, is displayed in 
figure 11b while the estimated KSV values of all tested flavonoids are 
summarized in Table 1 and graphed in figure 12.  
 
Figure 12. Estimated KSV values of all tested flavonoids obtained by fluorescence quenching 
analysis of reduced PDIA3 [0.5 x 10
-6
 M] in presence of increasing concentration of 
flavonoids (up to 2 x 10
-5
 M). Data are reported as mean and standard deviation of at least 
three independent experiments. 
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As shown in figure 12, a different degree of quenching was observed in 
presence of all tested molecules. The decrease of fluorescence may indicate 
that the microenvironments of tryptophan residues in PDIA3 were altered due 
to the interaction with tested compounds. The apparent binding constants 
(Kb) and the number of binding sites (n) were calculated using the equation 
described by Bi et al. [Bi et al., 2005], as previously reported [Trnkova et al., 
2013]:  
log((F0 – F)/F) = nlogKb – nlog(1/([Lt]-n(F0 – F)[Pt]/F0))   
where F0 and F are the fluorescence intensities at 338 nm before and after the 
addition of the quencher, [L] and [Pt] are the ligand and the total protein 
concentrations, respectively. The number of binding sites (n) and the binding 
constant (Kb) were obtained by plotting log((F0 – F)/F) versus log(1/([Lt]-
n(F0 – F)[Pt]/F0)) using the reiterative calculation process described by Sun 
et al. [Sun et al., 2010], assuming a similar affinity for each binding site. The 
dissociation constant was calculated from the binding constant (Kd = 1/Kb). 
The estimated KSV, Kb and Kd values that characterize the interaction of 
PDIA3 with tested flavonoids are summarized in Table 1.  
From our data it is evident that the protein binds most of the tested 
substances, with an estimated dissociation constant within the 10
-5
 M range. 
However two molecules are characterized by the highest binding constants: 
eupatorin and eupatorin-5-methyl ether, with a Kd around 1.0x10
-5
 M, 
followed by apigenin with a Kd of 1.7x10
-5
 M. These molecules, showing the 
highest affinity toward PDIA3, display an intermediate hydrophilicity degree, 
if compared with the other flavonoids tested in this study. These observations 
suggest that a specific degree of hydrophilicity is required to stabilize the 
interaction of the flavone backbone with the protein. 
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Table 1. Data were calculated from fluorescence quenching analysis using 0.5*10
-6 
M 
PDIA3 in reduced conditions (pH 7.4, 25°C) and increasing concentration (0 to 10*10
-6 
M) 
of different flavonoids. KSV are reported as mean and standard deviation of at least three 
independent experiments. The number of binding sites (n), the binding constant (Kb) and the 
dissociation constant (Kd) were estimated using the equation described by Bi et al. [Bi et al., 
2005] and the reiterative calculation process described by Sun et al. [Sun et al., 2010]. 
 
Flavonoid KSV  
(M-1) 
n Kb  
(M-1) 
Kd  
(M) 
Flavone     
Trimethoxyflavon 22209 ± 484 0,897 18123 5,52·10-5 
Eupatorin-5-methylether  90016 ±1875 1,079 90440 1,11·10-5 
Eupatorin 89362 ±688 1,163 96729 1,03·10-5 
Apigenin 54332 ±1185 1,083 58739 1,70·10-5 
Apigenin-7-glucoside  43961 ±673 1,060 47287 2,11·10-5 
Luteolin-7-glucoside  31601 ±484 1,061 34557 2,89·10-5 
Flavanone     
Naringenin  16900 ±352 1,053 17295 5,78·10-5 
Isoflavone     
Genistein  22953 ±435 1,085 24409 4,10·10-5 
Flavonol     
Rhamnetin  28462 ±295 1,034 30110 3,32·10-5 
Isorhamnetin  36109 ±1271 0,955 32516 3,08·10-5 
3-O-methyl-quercetin  41110 ±794 1,090 45719 2,19·10-5 
Fisetin 33164 ±542 1,076 36862 2,71·10-5 
Kaempferol 28423 ±982 0,968 26000 3,85·10-5 
Morin  24063 ±265 1,035 25613 3,90·10-5 
Quercetin  46226 ±1406 0,877 38987 2,56·10-5 
Quercitrin 29211 ±483 1,068 32288 3,10·10-5 
Isoquercetin 25738 ±367 1,077 29073 3,44·10-5 
Rutin  45197 ±465 0,960 45527 2,20·10-5 
Anthocyanin     
 
Cyanidin 
 
29761 ±635  0,992 29257 3,42·10-5 
 
We also observed that apigenin, genistein and naringenin that share similar 
functional groups, show different affinity for PDIA3. This difference could 
be explained by the specific position and orientation of the B ring. In 
naringenin the B ring on the C2 position is differently oriented respect to A 
and C rings while it is also differently positioned (C3) in genistein if 
compared with apigenin (3D models of default conformers are shown in Fig. 
13).  
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Figure 13. 3D models of default conformers for apigenin (CID 5280443), genistein (CID 
5280961) and naringenin  (CID 932) generated by PubChem 
(https://pubchem.ncbi.nlm.nih.gov).  
 
Hence, it can be hypothesized that the more parallel orientation between the 
aromatic rings A and B, mainly evident in flavones, is an important feature 
for the binding to PDIA3. 
For some flavonoids, the binding analysis was also extended to the isolated 
a’ domain. Similar values for the binding constants were estimated, with 
some flavonoids showing a slightly better affinity for the whole protein 
respect to the isolated domain. Even in this case, the molecules that show the 
greatest affinity are the flavones eupatorin, eupatorin-5-methyl ether and 
apigenin.  
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Table 2. Dissociation constant (Kd) were calculate from fluorescence quenching analysis 
using 1*10
-6 
M a’ domain and increasing concentration of different flavonoids. 
 
Flavonoid Kd 
(M) 
Flavone  
Eupatorin-5-methylether  1,56·10-5 
                                         Eupatorin 1,62·10-5 
Apigenin 1,71·10-5 
Flavonol  
Rhamnetin  3,04·10-5 
Isorhamnetin  2,95·10-5 
3-O-methyl-quercetin  1,94·10-5 
Fisetin 2,66·10-5 
Morin  3,58·10-5 
Quercetin  3,11·10-5 
Quercitrin 3,01·10-5 
Isoquercetin 4,38·10-5 
Rutin  2,69·10-5 
 
4.1.2 Effect of flavonoids on the PDIA3 redox activity 
To verify if the interaction between flavonoids and PDIA3 may have an 
effect on protein functions, the disulfide reductase activity was tested. For 
most of the analyzed molecules the effect on the redox activity of the protein 
was negligible. However, some flavonoids, in particular the flavones 
eupatorin and eupatorin-5-methyl ether, showed an evident inhibitory effect, 
up to 40%. Others, such as morin, quercetin and cyanidin, had a less marked 
inhibition, approximately 20% (Fig. 14). 
Apigenin, which showed a binding affinity close to eupatorin, had no evident 
effect on the protein activity. It is possible that the less polar degree, that 
characterizes eupatorin and eupatorin-5-methyl ether, may play a significant 
role. 
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Figure 14.  Comparison of flavonoid effect (at 20 μM concentration) on PDIA3 reductase 
activity. Plots are displayed as mean and standard deviations of at least six independent 
measurements. Data were analyzed by Dunnett’s test comparing PDIA3 activity in presence 
of each flavonoid with the activity of untreated protein. Significant differences (p < 0.01) are 
marked with asterisks.  
 
On the basis of these results, we hypothesize that, at least for those molecules 
showing a marked inhibitory effect on redox activity, the contact region of 
interaction between the flavonoid structure and PDIA3 should involve the 
active site. However, since we used a simple substrate like DiE-GSSG to 
measure the redox activity, we cannot exclude that the inhibitory effect of all 
flavonoids could be different towards more physiological substrates. 
 
4.1.3 Effect of flavonoids on the DNA binding property of PDIA3  
We also evaluated by EMSA analysis the effect of flavonoids on the DNA 
binding property of the protein (data not shown). None of tested flavonoids 
showed an appreciable effect on the DNA binding activity of the protein, 
differently from what previously reported for galloylated catechins [Trnkova 
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et al., 2013]. The presence in these molecules of a galloyl moiety linked to 
the C3 position is probably responsible for a different type of interaction that 
may extend to a protein region important to the contact with DNA (Fig. 15).  
 
 
Figure 15.  3D models of default conformers for eupatorin (CID 97214), quercetin (CID 
5280343) and epigallocatechin gallate (CID 65064) generated by PubChem. The estimated 
Kd values that characterize the interaction of PDIA3 with the three flavonoids, the 
percentage of inhibition of protein redox activity and the effect on DNA binding are also 
reported (epigallocatechin gallate data were from Trnkova et al., 2013). 
 
In that case, we hypothesized that the galloyl moiety on the C3 position could 
prevent the DNA binding activity interacting with a β-strand region close to 
the redox active site. Upon protein oxidation, such region can undergo to a 
conformational change that is essential for the interaction with the DNA 
[Grillo et al., 2007]. In this report none of the molecules analyzed have such 
effect. So we suggest that flavonoids interact with the same protein region 
containing the tryptophan residues close to the active sites, as suggested from 
the quenching measurements. However, this interaction may differently 
extend depending on the flavonoid structure and on specific contacts between 
flavonoids functional groups and aminoacidic residues on the protein surface. 
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4.2 Involvement of PDIA3 in β-amyloid deposits 
4.2.1 β-amyloid peptide treatment causes a decrease in PDIA3 protein 
but not in mRNA levels in SH-SY5Y cells 
To study the involvement of PDIA3 in β-amyloid deposits and in 
Alzheimer’s disease [Erickson et al., 2005; Tohda et al., 2012], we used SH-
SY5Y as a model of neuronal cell line and we treated them with the 25-35 
fragment of the amyloid β peptide. This peptide is highly toxic, displays 
extremely rapid aggregation, enhanced neurotoxicity and increases oxidative 
stress. First of all, we assessed the viability of SH-SY5Y under increasing 
concentrations of Aβ25-35.  
 
 
 
 
As shown in figure 16, Aβ25-35 treatment decreased cell viability of SH-
SY5Y cells in a concentration dependent manner. The ER stress activator 
Figure 16. Cell viability of SH-SY5Y after exposure to Aβ25–35 and thapsigargin (Tg) for 
24h. The graph is the result of the average of three independent experiments.  
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thapsigargin was used as positive control. Given this result for the next 
experiments we decided to use the amyloid β peptide at a concentration of 
50μM. 
SH-SY5Y cells were treated with 50μM Aβ25-35 for 24 hours and after cell 
lysis the expression levels of PDIA3 were analysed through western blot. 
     
 
Figure 17. Proteins were extracted from SH-SY5Y cells before and, after treatment with 50 
μM Aβ25-35 (Aβ) for 24hours, subjected to western blot analysis and revealed with different 
antibodies: anti-PDIA3 (on the top) and anti-βactin (on the bottom). 293T cells PDIA3 
silenced (shPDIA3) and 293T cells transfected with srambled RNA (shCTRL) were used as 
controls. The western blot quantification is presented as a grouped bar chart with error bars. 
Each bar represents the intensity means  ± s.d. of blots from three independent experiments. 
 
Aβ25-35 treatment induced a decrease in PDIA3 protein levels of about 20%. 
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293T cells shPDIA3 were used as positive control. This result could suggest 
that the stress induced by Aβ25-35 causes the cell to trigger a defence that 
lead to a decrease in PDIA3 levels. To investigate whether this effect was due 
to a transcriptional regulation response, SH-SY5Y cells, treated with Aβ25-
35 for 24 hours, were subjected to total RNA extraction, cDNA synthesis and 
qRT-PCR using specific primers to detect PDIA3 mRNA levels. Results 
obtained from qRT-PCR analysis are shown in the following figure: 
 
Figure 18. SH-SY5Y cells were treated with 50 μM Aβ for 24h. After total RNA extraction 
and cDNA synthesis, we performed a realtime PCR using proper primers to detect PDIA3 
mRNA levels (see material and methods). 293T cells PDIA3 silenced (shPDIA3) and 293T 
cells transfected with srambled RNA (shCTRL) were used as controls. The results presented 
here shows PDIA3 mRNA levels, normalized for β-actin, expressed in arbitrary units (AU). 
The results shown are the results of the average of three independent experiments. 
 
Data shown in figure 18 indicates that the reduction in PDIA3 protein levels, 
observed in the western blot analysis, was not due to a decrease in mRNA 
levels. 293T shPDIA3 cells were used as positive control. 
As further evidence, SH-SY5Ycells were treated with 50μM Aβ25-35 for 24 
hours in presence or absence of 100 μg/mL cyclohexamide. 
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Figure 19. Proteins were extracted from SH-SY5Y cells after treatment with 50 μM Aβ25-
35 for 24hours in presence or absence of 100 μg/mL cycloheximide, subjected to western 
blot analysis and revealed with anti-PDIA3 antibody. The western blot quantification is 
presented as a grouped bar chart with error bars. Each bar represents the intensity means  ± 
s.d. of blots from three independent experiments.  
 
As shown in figure 19, when cells were treated for 6h with the protein 
synthesis inhibitor cycloheximide, the decrease in PDIA3 protein levels 
induced by Aβ was more evident, going from 25% (Aβ treatment) to 50% 
(Aβ-cycloheximide co-treatment).  
 
4.2.2 The 25-35 fragment of the amyloid β peptide does not induce ER 
stress in SH-SY5Y cells 
Since it has been reported that aggregates of Aβ 1-42 peptide induced ER 
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stress in neuronal cells [Chafekar et al., 2007; Lee et al., 2010], we wanted to 
verify if the decrease in PDIA3 levels could be a consequence of the UPR 
activation induced by Aβ. To test that, SH-SY5Y cells were treated with Aβ 
peptide for 24 hours and different UPR mediators were investigated. First, 
after cell lysis the expression levels of the ER chaperone BIP were analysed 
through western blot. 
 
 
Figure 20. Proteins were extracted from SH-SY5Y cells after treatment with 50 μM Aβ25-
35 for 24h or Thapsigargin (TG) for 9h, subjected to western blot analysis and revealed with 
anti-BIP and anti-actin  antibody. The western blot quantification is presented as a grouped 
bar chart with error bars. Each bar represents the intensity means ± s.d. of blots from three 
independent experiments.  
 
As noticeable in the figure above, there was no significant differences in BIP 
protein levels after 24 hours of treatment with Aβ 25-35. The ER stress 
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activator thapsigargin was used as a positive control. 
Afterwards we analyzed the levels of the spliced form of XBP1, another UPR 
mediator, through RT-PCR, using a couple of primers which recognize both 
the spliced and unspliced form of XBP1. 
 
 
Figure 21. SH-SY5Y cells were treated with Aβ 50 μM for 24hours or thapsigargin (TG) 0.5 
μM for  9 hours. After RNA extraction, Xbp-1mRNA splicing was determined by PCR. PCR 
products were separated by electrophoresis on 3% agarose gels. Products resulting from 
unspliced (“u”) an spliced (“s”) Xbp-1 mRNA are indicated. Asterisk identifies a hybrid 
amplicon resulting from spliced and unspliced Xbp-1 mRNA. 
 
Aβ did not cause splicing of XBP1, as evident from the absence of the 
spliced form of XBP1 in the figure 21. Thapsigargin, on the other hand, 
caused ER stress and consequent activation of IRE1, which cleaves the XBP1 
mRNA to obtain the active transcription factor represented by the spliced 
XBP1, indicated by the bottom band in figure 21. 
To check if there was an earlier activation of UPR, SH-SY5Y cells were 
treated for 4 and 8 hours with amyloid β peptide and western blot analysis 
was performed to determine BIP levels. 
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Figure 22.  Proteins were extracted from SH-SY5Y cells after treatment with 50 μM Aβ25-
35 for 4 and 8 hours or Thapsigargin (TG) for 9hours, subjected to western blot analysis and 
revealed with anti-BIP and anti-actin  antibody. The western blot quantification is presented 
as a grouped bar chart with error bars. Each bar represents the intensity means  ± s.d. of blots 
from three independent experiments.  
 
As shown in figure 22, after 4 and 8 hours of treatment with Aβ25-35 there 
was no increase in BIP levels, suggesting that no UPR occurs after Aβ-
induced stress in SH-SY5Y cells. To further prove that there was no UPR 
activation, we also checked mRNA levels of CHOP and of the spliced form 
of XBP1 through RT-qPCR. As shown in figure 23, there was no increase in 
XBP1 spliced and CHOP mRNA levels after Aβ treatment. All these data 
confirmed that the decrease in the PDIA3 levels, induced by Aβ peptide 
treatment, was not due to ER stress and consequent UPR activation. 
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Figure 23.  SH-SY5Y cells were treated with 50 μM Aβ for 4 and 8 hours and with 0.5 μM 
Thapsigargin (TG) for 6 hours as positive control. Untreated cells were used as a control. 
After total RNA extraction and cDNA synthesis, we performed a realtime PCR using proper 
primers to detect XBP1s, CHOP and β-actin mRNAs. 
 
4.2.3 β-amyloid peptide treatment does not induce an PDIA3 
degradation via proteasome in SH-SY5Y cells 
Given the results obtained, we hypothesized two possible scenarios as a 
cellular response to Aβ25-35 treatment: PDIA3 protein degradation or 
secretion. To check if the decrease in PDIA3 protein levels under Aβ 
treatment was due to degradation dependent on the proteasome, the SH-
SY5Y cell line was treated with Aβ in presence or absence of the specific 
proteasome inhibitor MG132. As shown in figure 24, there was no difference 
in PDIA3 proteins levels under Aβ treatment in presence or absence of 
MG132, meaning that the decrease in PDIA3 levels induced by Aβ peptide is 
not a consequence of the protein degradation through proteasome. 
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Figure 24.  Proteins were extracted from SH-SY5Y cells after treatment with 50 μM Aβ25-
35 (Aβ) for 24hours in presence or absence of 5 μM MG132 (8 hours), subjected to western 
blot analysis and revealed with different antibodies: anti-PDIA3 (on the top) and anti-βactin 
(on the bottom). The western blot quantification is presented as a grouped bar chart 
with error bars. Each bar represents the intensity means ± s.d. of blots from three 
independent experiments. 
 
4.2.4 β-amyloid peptide treatment induces PDIA3 delocalization and 
secretion in SH-SY5Y cells 
Given the results obtained, the next step was to verify if the decrease in 
PDIA3 protein levels was due to secretion.  
First of all, we analyzed PDIA3 subcellular localization under Aβ25-35 
treatment. SH-SY5Y cells were grown on microscope slides and treated with 
50 μM Aβ25-35 for 24 hours, cells were crosslinked with formaldehyde and 
permeabilized. Then we performed an immunostaining using an anti-PDIA3 
antibody and a TRITC-conjugated secondary antibody. Nuclei were 
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visualized with DAPI staining. What obtained was then observed at a 
fluorescence microscope (Leica). 
 
 
 
Figure 25.  SH-SY5Y cells were grown on microscope slides, treated for 3, 6 and 24h with 
50 μM Aβ25-35, cross-linked with formaldehyde and permeabilized. Immunostaining was 
performed using anti-PDIA3 antibody and TRITC-conjugated secondary antibody. DAPI 
was used to stain nuclei. Cells were observed at a Leica fluorescence microscope. 
 
  
From what is visible from figure 25, in the untreated sample (CTR), PDIA3 
was mainly localized in the perinuclear region (compatible with ER 
localization), while it seems that after 24 hours, β-amyloid peptide induced 
PDIA3 delocalization toward the plasma membrane. 
Considering these data, our hypothesis is that β-amyloid peptide could lead to 
PDIA3 translocation from the ER to the membrane surface and afterwards 
PDIA3 secretion in the extracellular space in order to counteract the toxic 
action of β-amyloid present in the culture medium. This is not the first 
evidence to show a possible PDIA3 secretion. Previous studies reported 
secretion of this ER resident protein even if it contains an ER retention signal 
[Hirano et al., 1995; Furie and Flaumenhaft, 2014; Dihazi et al., 2013]. 
Moreover this has been demonstrated for other ER chaperons [Genereux et 
al., 2015; Hahm et al., 2013; Obeid et al., 2007]. 
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To test our hypothesis we treated SH-SY5Y cells with 50 μM Aβ25-35 at 
different times and then subjected the culture media to Na-deoxycholate-TCA 
protein precipitation, acetone washing and proteins solubilization in SDS. 
Then we performed a western blot analysis using anti-PDIA3 antibody.  
 
 
 
 
Figure 26.  Secreted proteins from untreated (C) and Aβ25-35 treated (AB) SH-SY5Y cells 
were obtained subjecting culture media to Na-deoxycholate-TCA precipitation. Proteins 
were then analyzed by means of western blot using anti-PDIA3 antibody. The western blot 
quantification is presented as a grouped bar chart with error bars. Each bar represents the 
intensity means ± s.d. of blots from three independent experiments. 
 
The previous figure shows that SH-SY5Ys could secrete PDIA3 in absence 
of any treatment, but there was an increase in extracellular PDIA3 after 
treating cells with Aβ25-35 for one hour. 
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Furthermore, to check if PDIA3 was secreted through the canonical secretory 
pathway, SH-SY5Y cells were treated with Aβ for 24h in presence or 
absence of the secretory trafficking inhibitor brefeldin A. Total proteins were 
extracted and subjected to western blot analysis to estimate PDIA3 levels. 
 
 
 
 
Figure 27.  Proteins were extracted from SH-SY5Y cells after treatment with 50 μM Aβ25-
35 (Aβ) for 24hours in presence or absence of 50 ng/mL Brefeldin A (8 hours), subjected to 
western blot analysis and revealed with different antibodies: anti-PDIA3 (on the top) and 
anti-βactin (on the bottom). The western blot quantification is presented as a grouped bar 
chart with error bars. Each bar represents the intensity means ± s.d. of blots from three 
independent experiments. 
 
 
From the results presented in figure 27, it is evident that brefeldin A did not 
rescue PDIA3 levels, meaning that this protein was not secreted through the 
canonical Golgi-mediated secretory pathway, under Aβ treatment. 
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4.3 Discriminating between IRE1 activities 
4.3.1 IRE1-GFP cleaves XBP1 mRNA and clusters in foci 
During my research activity at The Children’s Hospital of Philadelphia, I 
focused my attention on the study of IRE1 activities. For this purpose we 
used the human haploid cell line, HAP1, knock-out for IRE1. First of all we 
checked the expression levels of IRE1 in HAP1 cells, both IRE1 +/+ and -/-, 
through western blotting analysis. 
 
Figure 28. Proteins were extracted from HAP1 cells parental (IRE1+/+) and IRE1 KO 
(IRE1-/-), subjected to western blot analysis and revealed with anti IRE1 antibody.  
 
 
As shown in the figure 28, the expression of IRE1 was completely abolished 
in the HAP1 IRE1 knock-out cells, while IRE1+/+ HAP1s showed a band 
around 110-120 kDa, corresponding to endogenous IRE1. In second place we 
assessed the IRE1 capability to cleave XBP1 mRNA through the splicing 
assay under ER stress. The figure 29 shows that HAP1 cells with endogenous 
IRE1 were able to cleave XBP1 mRNA in response to ER stress, as visible 
from the bottom band in the gel (s=spliced), while, as expected, IRE1 -/- 
HAP1s did not perform the XBP1 splicing. 
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Figure 29. Parental (IRE1+/+) and IRE1 KO (IRE1-/-) HAP1 cells were treated with 
Thapsigargin 0.5 μM for 4h. Total RNA was extracted and subjected to reverse transcription 
into CDNA. Xbp-1mRNA splicing was determined by PCR. PCR products were separated 
by electrophoresis on 3% agarose gels. Products resulting from unspliced (“u”) an spliced 
(“s”) Xbp-1 mRNA are indicated. Asterisk identifies a hybrid amplicon resulting from 
spliced and unspliced Xbp-1 mRNA. 
 
To begin studying IRE1activities, a GFP-tagged fluorescent human IRE1α 
fusion construct, IRE1–3-Flag-6-Histidine (3F6HGFP), with the fluorescent 
tag located in the non-conserved linker between the transmembrane domain 
and the kinase domain, was previously cloned in our lab (Fig. 30).The tag 
was placed in this area of the protein because in a previous study it was 
reported that yeast Ire1 tagged in the same position was functional, whereas 
the GFP tag in the C- or N-terminal abolished IRE1 functionality [Aragón et 
al., 2009].  
 
Figure 30.  Schematic representation of IRE1-GFP construct. LD=Luminal domain, 
TM=transmembrane domain, L=linker domain, K=kinase domain, R=endoribonuclease 
domain. 3F6H-GFP=inserted tag consisting of three FLAG epitopes followed by six 
histidines and a GFP. [Li et al., 2010] 
 
We next established a stable IRE1-/- HAP1 cell line, in which the expression 
of WT-IRE1GFP and several point mutants was regulated through a 
doxycycline inducible system. Since it has been reported that, when IRE1 is 
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overexpressed, there is a spontaneous activation of its endoribonuclease 
domain, we first made sure not to induce IRE1 overexpression in our 
working conditions.. In this regard, IRE1-/- HAP1 cells, stably transduced 
with WT IRE1GFP and several point mutants, were treated with 1μg/mL of 
doxycycline for 24 hours to allow the expression of the recombinant protein. 
Total proteins were extracted and subjected to western blotting. 
 
Figure 31. Proteins were extracted from HAP1 cells expressing endogenous IRE1 (IRE1+/+) 
and IRE1 KO (IRE1-/-) cells expressing WT-IRE1GFP and its mutants treated with 1μg/mL 
doxycycline , subjected to western blot analysis and revealed with anti IRE1 antibody. 293T 
cells transfected with pCAX-IRE1GFP were used as a model of IRE1 overexpression. The 
western blot quantification is presented as a grouped bar chart with error bars. Each bar 
represents the intensity means  ± s.d. of blots from three independent experiments. 
 
As can be seen in figure 31, at the doxycyline concentration used, there was 
not overexpression of exogenous compared to the endogenous IRE1. On the 
other hand, IRE1 overexpression can be clearly observed in 293Ts 
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transfected with pCAX-IRE1GFP, which is a plasmid in which the 
expression of the protein of interest is under the control of a strong 
constitutive promoter. Once established that we were not working in 
overexpression conditions, we verified IRE1GFP ability to get activated in 
response to ER stress. After the expression of WT-IRE1GFP in IRE1-/- 
HAP1 cells, induced with 1μg/mL doxycycline, cells were treated with 
0.2μM of the ER stress activator thapsigargin for different time points. Total 
RNA was extracted, subjected to reverse transcription into cDNA and PCR in 
order to detect the XBP1 mRNA splicing. 
 
Figure 32.  IRE1-GFP IRE1−/− HAP1s were treated with doxycycline (Dox) for 24h to 
induce IRE1GFP expression. After withdrawing of Dox, cells were treated with thapsigargin 
(TG) 0.2 μM for  different times.Xbp-1mRNA splicing was determined by PCR. Products 
resulting from unspliced (“u”) an spliced (“s”) Xbp-1 mRNA are indicated. Asterisk 
identifies a hybrid amplicon resulting from spliced and unspliced Xbp-1 mRNA. 
As shown in figure 32, IRE1GFP fusion protein restored splicing of XBP-1 
RESULTS AND DISCUSSIONS  
 
60 
 
mRNA in response to ER-stress. The next step was to evaluate the ability of 
IRE1GFP, under induction of ER stress with tunicamycin (Tm), to localize 
into discrete foci in the ER membrane. 
 
 
Figure 33. IRE1-GFP IRE1−/− HAP1s were treated with doxycycline (Dox) for 24h to 
induce IRE1GFP expression. At time 0, medium was replaced by medium containing no Dox 
but 4 μg/mL tunicamycin (Tm) to induce ER stress. IRE1GFP localization was evaluated 
over 8h time course.  Percentage of cells with IRE1 foci was determined as quantification of 
time course experiment. 
 
From figure 33, it appears that IRE1GFP clustered into many small foci after 
2 h of Tm treatment. Upon persistent stress, these foci converted into fewer 
and larger ones and after 6 h of Tm treatment, we observed that IRE1 foci 
started to dissociate and completely resolved after 8 h. Moreover it was 
evident that a concomitant reappearance of fluorescence staining of the ER 
took place, suggesting a diffused redistribution of IRE1GFP over the ER 
membrane. These data suggest that the percentage of cells with IRE1 foci and 
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the Xbp-1 mRNA splicing follow a similar kinetic, with the maximum of 
activity after 2 and 4 hours. Furthermore, IRE1 activation was transitory even 
if the ER stress persisted. 
 
4.3.2 An IRE1GFP defective luminal domain mutant is completely 
inactive 
The next step of our study was to evaluate the effects of a mutation in the 
luminal domain, which impairs IRE1 dimerization [Zhou et al., 2006], on 
IRE1 activities. In this respect, IRE1-/- HAP1 cells expressing D123P-
IRE1GFP mutant, were treated with the ER stressor thapsigargin and XBP1 
splicing assay was performed.  
 
Figure 34. WT-IRE1GFP and D123P-IRE1GFP IRE1−/− HAP1s were treated with 
doxycycline (Dox) for 24h to induce IRE1GFP expression. After withdrawing of Dox, cells 
were treated with thapsigargin (TG) 0.2 μM for different times. Xbp-1mRNA splicing was 
determined by PCR. Products resulting from unspliced (“u”) an spliced (“s”) Xbp-1 mRNA 
are indicated. Asterisk identifies a hybrid amplicon resulting from spliced and unspliced 
Xbp-1 mRNA. 
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As can be observed in figure 34, the mutation of the aspartate 123 into a 
proline, impairing IRE1 dimerization, almost completely abolished IRE1 
RNase activity, in comparison to WT-IRE1. 
Next we investigated the ability of the D123P-IRE1GFP mutant to associate 
in clusters under ER stress. 
 
Figure 35. D123P-IRE1GFP IRE1−/− HAP1s were treated with doxycycline (Dox) for 24h 
to induce D123P-IRE1GFP expression. At time 0, medium was replaced by medium 
containing no Dox but 4 μg/mL tunicamycin (Tm) to induce ER stress. D123P-IRE1GFP 
localization was evaluated over 8h time course.   
 
As can be seen in the figure above, the D123P mutant of IRE1, which is 
defective in self-association of the luminal domain, failed to cluster into foci 
upon tunicamycin treatment. From these data it was evident that a mutation 
in the luminal domain of IRE1, which impairs dimerization, caused a total 
suppression of IRE1 activity. 
 
4.3.3 An IRE1GFP defective endoribonuclease domain mutant does 
not cleave XBP1 mRNA but clusters irreversibly into ER membrane 
For the next experiments we used an IRE1 mutant with a defective 
endoribonuclease domain [Tirasophon et al., 2000]. IRE1-/- HAP1 cells 
expressing K907A-IRE1GFP mutant, were treated with thapsigargin to 
induce ER stress and XBP1 splicing assay was performed. 
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Figure 36.  WT-IRE1GFP and K907A-IRE1GFP IRE1−/− HAP1s were treated with 
doxycycline (Dox) for 24h to induce IRE1GFP expression. After withdrawing of Dox, cells 
were treated with thapsigargin (TG) 0.2 μM for  different times. Xbp-1mRNA splicing was 
determined by PCR. Products resulting from unspliced (“u”) an spliced (“s”) Xbp-1 mRNA 
are indicated. Asterisk identifies a hybrid amplicon resulting from spliced and unspliced 
Xbp-1 mRNA. 
 
As expected, the mutation of the lysine 907 into an alanine, which affects the 
RNase domain of IRE1, completely suppressed IRE1 capability to cleave the 
XBP1 mRNA. Further we evaluated the ability of this IRE1 mutant to 
relocalize into discrete foci in the ER membrane after induction of ER stress 
with tunicamycin. As shown in figure 37, K907A-IRE1GFP mutant clustered 
into big foci after 2 hours of tunicamycin treatment and it was evident that 
these big foci did not resolve over the time course experiment. This result 
was completely unexpected since from the data obtained from the WT protein 
it seemed that IRE1 clustering was related to its endoribonuclease activity. 
However the data obtained from this last experiment showed that IRE1 
clustering is independent from its endoribonuclease activity and that IRE1 
clustering initiation does not require a functional endoribonuclease domain. 
Moreover, a defect in this domain seemed to keep IRE1 in clusters over the 
time. 
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Figure 37. K907A-IRE1GFP IRE1−/− HAP1s were treated with doxycycline (Dox) for 24h 
to induce K907A-IRE1GFP expression. At time 0, medium was replaced by medium 
containing no Dox but 4 μg/mL tunicamycin (Tm) to induce ER stress. IRE1GFP 
localization was evaluated over 8h time course.  Percentage of cells with IRE1 foci was 
determined as quantification of time course experiment. 
 
To evaluate our hypothesis, we tested WT-IRE1GFP ability to associate in 
clusters under ER stress in presence of a known inhibitor of the RNase 
domain of IRE1, the small molecule 4μ8c [Cross et al.,2012]. As evident in 
figure 38, WT-IRE1GFP clustered into big foci after 2 hours of tunicamycin 
treatment in presence of the inhibitor 4μ8c and even in this case these big 
foci did not resolve over the time course experiment. 4μ8c is a small inhibitor 
which chemically interacts with the lysine 907 in the RNase domain of IRE1 
leading to inhibition of both XBP1 splicing and RIDD activity [Cross et al., 
2012]. 
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Figure 38. WT-IRE1GFP IRE1−/− HAP1s were treated with doxycycline (Dox) for 24h to 
induce IRE1GFP expression. At time 0, medium was replaced by medium containing no Dox 
but 4 μg/mL tunicamycin (Tm) and 16 μM 4μ8c. IRE1GFP localization was evaluated over 
8h time course. Percentage of cells with IRE1 foci was determined as quantification of time 
course experiment. 
 
Given these results, we can deduce that if the RNase domain of IRE1 is 
inhibited, either with a mutation (K907A) or using a small chemical inhibitor 
(4μ8c), IRE1 clusters in large foci in the ER membrane and these clusters do 
not resolve over the time. This could be explained by the existence of a 
negative feedback of the IRE1 RNase activity that could control IRE1 
clustering. In this scenario, when the RNase domain of IRE1 is inhibited, 
there is no control on IRE1 clustering and therefore IRE1 persists in clusters. 
Another explanation could be that, when IRE1 cannot act as an 
endoribonuclease, it could perform other activities that could be related to its 
cluster state, for instance the activation of the JNK pathway. Given that IRE1 
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phosphorylation is a key event in IRE1 activation we also decided to test the 
phosphorylation state of the K907A mutant under ER stress. In this regard 
IRE1-/- HAP1 cells expressing K907A-IRE1GFP were treated with 
thapsigargin to induce ER stress for different time points. Total proteins were 
extracted and subjected to western blotting using anti IRE1 and phospho-
IRE1 antibodies. 
 
Figure 39.  Proteins extracted from K907A-IRE1GFP IRE1-/- HAP1s, treated with 
increasing concentrations of doxycycline (Dox) for 24h to induce IRE1GFP expression and 
after that with thapsigargin (TG) 0.2 μM for  6 hours (a), and from IRE1+/+ HAP1s  treated 
with TG 0.2 μM for  6 hours (b), were subjected to western blot analysis and revealed with 
anti IRE1 and phospho-IRE1 antibodies. 
 
As shown in the previous figure, the K907A mutant persisted in a 
phosphorylated state under ER stress; moreover it showed basal 
phosphorylation even without ER stress (Fig. 39a). This could explain why 
this mutant clustered spontaneously in absence of any ER stressor, even if in 
a limited percentage, 30% (Fig.37) vs. 0% in WT-IRE1 (Fig.33). Conversely 
WT-IRE1 was reversibly phosphorylated after thapsigargin treatment: after 8 
hours of stress, IRE1 was completely dephosphorylated (Fig. 39b). As 
showed before in figure 33, WT IRE1 clusters resolved over the 8 hours 
treatment with thapsigargin. Considering all these data our hypothesis is that 
IRE1 ability to localize in foci within the ER membrane is strictly dependent 
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on its phosphorylation state.  
 
4.3.4 The flavonoid luteolin induces XBP1 splicing acting from the 
cytosol but does not induce IRE1 clustering. 
Until this point we investigated IRE1 activities upon ER stress, which is 
known to induce BIP dissociation from the IRE1 luminal domain, its 
dimerization, trans-autophosphorylation, conformational changes and 
consequent activation of the RNase domain. The next step was to study IRE1 
activities with a stimulus coming from the cytosol and not from the ER. To 
this end we used luteolin, a flavonoid which induces XBP1 splicing through 
direct binding to IRE1 at the interphase between the kinase and the 
endoribonuclease domain [Wiseman et al., 2010]. We treated IRE1+/+ HAP1 
cells with two concentrations of luteolin at different time points and 
performed the XBP1 mRNA splicing assay. 
 
Figure 40. IRE1+/+ HAP1 cells were treated with thapsigargin (TG) 0.2 μM for  6 hours or 
with two concentrations of luteolin for different times.  Xbp-1mRNA splicing was 
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determined by PCR. Products resulting from unspliced (“u”) an spliced (“s”) Xbp-1 mRNA 
are indicated. Asterisk identifies a hybrid amplicon resulting from spliced and unspliced 
Xbp-1 mRNA. 
As observed in the figure above, luteolin induced activation of the RNase 
domain of IRE1 in HAP1 cells. We then evaluated the ability of this 
flavonoid to cause localization of IRE1 into foci. To this end WT-IRE1GFP 
IRE1-/- HAP1 cells were treated with luteolin and IRE1GFP distribution was 
followed over the time.  
 
Figure 41. WT-IRE1GFP IRE1−/− HAP1s were treated with doxycycline (Dox) for 24h to 
induce IRE1GFP expression. At time 0, medium was replaced by medium containing no Dox 
but 50μM luteolin. IRE1GFP localization was evaluated over 8h time course.   
 
As illustrated in the figure 41, luteolin did not cause IRE1 reorganization in 
clusters, even if it binds and activates IRE1 endoribonuclease domain. 
Considering these results and knowing that phosphorylation plays a pivotal 
role in IRE1 activation, we investigated the ability of luteolin to induce IRE1 
phosphorylation. To this purpose IRE1+/+ HAP1 cells were treated with 
luteolin at two different concentrations for 2 hours. Total proteins were 
extracted and subjected to western blotting using anti IRE1 and phospho-
IRE1 antibodies.  
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Figure 42.  IRE1+/+ HAP1s were treated with thapsigargin (TG) 0.2 μM for  2 hours or with 
two concentrations of luteolin for 2 hours.  Proteins were extracted and subjected to western 
blot analysis and revealed with anti IRE1  and phospho-IRE1 antibodies.  
 
From the figure 42 there is a significative was a shift between the band of 
phospho IRE1 under TG and under luteolin treatment. This could mean that 
luteolin induces a different degree in IRE1 phosphorylation. It is known from 
literature that IRE1 can be phosphorylated in different residues and that 
phosphorylation in the activation loop is sufficient to activate XBP1 splicing 
(Fig. 43) [Prischi et al., 2014].  
 
Figure 43. Position of phosphorylation sites in IRE1 structure (adapted from Prischi et al., 
2014). 
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Therefore, we hypothesized that luteolin induces phosphorylation only in the 
IRE1 activation loop, leading to activation of its endoribonuclease domain 
and subsequent XBP1 splicing. Conversely IRE1 clustering could require 
phosphorylation in other residues. This could explain why luteolin did not 
induce IRE1 to localize into foci.  
 
4.3.5 L827P IRE1-GFP is a fortuitous inactive mutant found in our lab. 
When we first tried to recomplement IRE1-/- HAP1 cells with the 
doxycycline-inducible IRE1GFP, we performed the XBP1 mRNA splicing 
assay and surprisingly, as visible in the following figure, the exogenous IRE1 
was not able to cleave the XBP1 mRNA.  
 
Figure 44. IRE1GFP IRE1−/− HAP1s were treated with doxycycline (Dox) for 24h to 
induce IRE1GFP expression. After withdrawing of Dox, cells were treated with thapsigargin 
(TG) 0.2 μM for  different times. IRE1 +/+ HAP1 cells were used as positive control. Xbp-
1mRNA splicing was determined by PCR. Products resulting from unspliced (“u”) an spliced 
(“s”) Xbp-1 mRNA are indicated. Asterisk identifies a hybrid amplicon resulting from 
spliced and unspliced Xbp-1 mRNA. 
 
This result was completely unexpected, since we knew from the literature [Li 
et al., 2010] and from other IRE1GFP plasmids present in our lab that IRE1 
constructs with the GFP in the same position were completely active. In this 
respect we decided to sequence the whole IRE1GFP insert; what we found 
out was a single point mutation in a nucleotide which led to the mutation of 
the leucine in the position 827 into a proline. 
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Figure 45. DNA sequencing of the pLenti-IRE1GFP (active) and pTIGHT-IRE1GFP 
(inactive) plasmids. The mutation led to the conversion of the CTC triplet, which encodes for 
Leucine 827 into a CCC triplet, which encodes for a proline.  Mut, mutant type; Wt, wild-
type. 
 
This mutated residue is located between the kinase and the endoribonuclease 
domain of IRE1. The fact that a mutation not present in any of the catalytic 
domains of IRE1 led to the complete suppression of the IRE1 ability to 
cleave the XBP1 mRNA, encouraged us to investigate this new mutant of 
IRE1. To do that we followed the L827P IRE1GFP mutant localization in the 
ER membrane under ER stress over the time. 
 
Figure 46.  L827P-IRE1GFP IRE1−/− HAP1s were treated with doxycycline (Dox) for 24h 
to induce L827P-IRE1GFP expression. At time 0, medium was replaced by medium 
containing no Dox but 4 μg/mL tunicamycin (Tm) to induce ER stress. L827P-IRE1GFP 
localization was evaluated over 8h time course.   
 
As shown in figure 46, this mutant did not cluster in foci under ER stress. So 
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this mutant seemed to behave like the D123P mutant, which is completely 
inactive, since it affects IRE1 dimerization. In order to understand if this new 
mutant was unable to dimerize, as the D123P , we decided to check its effect 
on endogenous IRE1. In this regard, IRE1+/+ HAP1 cells, stably transduced 
with L827P-IRE1GFP mutant, were treated with increasing concentrations of 
doxycycline for 24 hours to allow the expression of the recombinant protein. 
The XBP1 mRNA splicing assay was performed under ER stress conditions. 
 
Figure 47.  L827P-IRE1GFP IRE1+/+ HAP1s were treated with increasing concentrations of 
doxycycline (Dox) for 24h to induce IRE1GFP expression. After withdrawing of Dox, cells 
were treated with thapsigargin (TG) 0.2 μM for  6 hours. Xbp-1mRNA splicing was 
determined by PCR. Products resulting from unspliced (“u”) an spliced (“s”) Xbp-1 mRNA 
are indicated. Asterisk identifies a hybrid amplicon resulting from spliced and unspliced 
Xbp-1 mRNA. 
 
As can be observed in figure 47, the L827P mutant inhibited endogenous 
IRE1 in a concentration-dependent manner, reaching an almost completely 
inhibition at concentrations of doxycycline between 5 and 10 μg/mL. If this 
mutant can inhibit endogenous IRE1, we deduced that, differently from the 
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D123P, it is able to dimerize. At this point we decided to better characterize 
this inhibitory mutation. Since it is known that phosphorylation is important 
in IRE1 activation, the next step would be to check the phosphorylation state 
of this mutant. For some technical issues we were not able to investigate this 
aspect yet, but we checked the phosphorylation of endogenous IRE1 in 
presence of this mutant. IRE1+/+  HAP1 cells, stably transduced with L827P-
IRE1GFP mutant, were treated with increasing concentrations of doxycycline 
for 24 hours to allow the expression of the recombinant protein.  
 
Figure 48. L827P-IRE1GFP IRE1+/+ HAP1s were treated with increasing concentrations of 
doxycycline (Dox) for 24h to induce IRE1GFP expression. After withdrawing of Dox, cells 
were treated with thapsigargin (TG) 0.2 μM for  6 hours.  Proteins were extracted and 
subjected to western blot analysis and revealed with anti IRE1  and phospho-IRE1 
antibodies.  
After treatment with thapsigargin for 6 hours to induce IRE1 
phosphorylation, cells were lysed and total proteins were extracted and 
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subjected to western blotting using anti IRE1 and phospho-IRE1 antibodies. 
As shown in figure 48, the increase in the L827P mutant expression, achieved 
by increasing the doxycycline concentration, led to a decrease in the 
phosphorylation state of endogenous IRE1. These data suggest that this new 
mutant of IRE1 inhibits XBP1 splicing activity of IRE1 by inhibiting its 
phosphorylation. It is known from the literature that IRE1 phosphorylation 
causes conformational changes in the kinase and RNase domains of IRE1 
necessary for IRE1 activation. As reported above, the flavonoid luteolin 
binds and activates XBP1 splicing activity of IRE1. The binding of this 
flavonoid occurs in the interphase between the kinase and endoribonuclease 
domains of IRE1 [Wiseman et al., 2010], the same region in which is located 
the L827P mutation. Knowing this, we decided to treat IRE1-/- HAP1 cells 
expressing the L827P-IRE1GFP with luteolin and to perform the XBP1 
splicing assay. 
 
Figure 49.  L827P IRE1GFP IRE1−/− HAP1s were treated with doxycycline (Dox) for 24h 
to induce L827P IRE1GFP expression. After withdrawing of Dox, cells were treated with 
thapsigargin (TG) 0.2 μM for  different times. IRE1 +/+ HAP1 cells were used as positive 
control. Xbp-1mRNA splicing was determined by PCR. Products resulting from unspliced 
(“u”) an spliced (“s”) Xbp-1 mRNA are indicated. Asterisk identifies a hybrid amplicon 
resulting from spliced and unspliced Xbp-1 mRNA. 
 
From the figure above it was evident that luteolin did not rescue L827P 
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IRE1GFP ability to perform XBP1 splicing. As above reported, IRE1 
activation requires its dimerization, phosphorylation and conformational 
changes which lead to juxtaposition of the RNase active sites of two adjacent 
protomers, orienting the relevant residues for catalysis (Fig 50a). Luteolin 
binds a pocket between the kinase and endoribonuclease domains of IRE1 
and activates XBP1 splicing activity of IRE1 (Fig. 50b) [Wiseman et al., 
2010]. In the case of the L827P mutant luteolin does not induce XBP1 
splicing. We do not know yet if this result is due to the fact that luteolin 
cannot bind this mutant or if the binding occurs but the conformational 
changes required for activation are prevented (Fig. 50c). In both cases we 
think that the mutation of a leucine residue into a more rigid amino acid, such 
as proline, completely abolishes the ability of the RNase domain to reach the 
conformation required for its activity.   
 
 
Figure 50.  Schematic representation of  IRE1activation. WT-IRE1 in presence of ER stress 
dimerizes through its luminal domain and undergoes conformational changes that leads to 
RNase domain activation (a). Luteolin induces conformational changes without ER stress 
with consequent RNase domain activation in WT-IRE1 (b), but not in L827P-IRE1 (c).
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5. CONCLUSIONS 
In the first part of this study, the interaction of different flavonoids with 
PDIA3 and their effect on protein reductase activity were evaluated. Two 
molecules, eupatorin and eupatorin-5-methyl ether, showed the highest 
affinity for PDIA3 with a Kd near to 1.0x10-5 M. They also showed a 
noticeable inhibitory effect on disulphide reductase activity of PDIA3, but 
they did not significantly affect its DNA binding activity. The backbone 
structure of these two flavones is characterized by a more stable 
conformation where B and A rings are almost parallel (Fig. 13). This 
structure, associated with a definite degree of polarity, due to the presence of 
several methoxyl- groups, seems to be an important feature to determine a 
good affinity toward PDIA3. We can hypothesize that flavones interact with 
a region of the protein involving the tryptophan residues close to the redox 
site and given that PDIA3 does not contain any evident deep cavity or slot 
where this kind of ligands can bind, the binding of flavonoids may occur 
mainly via a flat interaction with the protein surface. Therefore, the planarity 
of the molecule as well as the number and specific position of its functional 
groups (hydroxyl-, methoxyl- and carbohydrates) will definitively play a 
major role to determine the affinity for the protein. In conclusion, eupatorin 
and eupatorin-5-methyl ether represent leading compounds for the binding to 
PDIA3 and for the inhibition of its redox activity. Further experiments are 
required to better characterize the effect of flavonoids on PDIA3 and to 
understand if some of the biological activities of these compounds are 
depending on the interaction with PDIA3. Since these flavones and PDIA3 
are both involved in proliferative and carcinogenic processes, our in vitro 
findings on their interaction suggest that some of the biological effects of 
CONCLUSIONS  
 
77 
 
flavones could be mediated by modulation of PDIA3 activity. Additionally, 
this study will help to define and identify compounds to be used as selective 
inhibitors/modulators of PDIA3 biological activities. 
Regarding the implications of PDIA3 in β-amyloid deposits and Alzheimer’s 
disease, we observed that β-amyloid peptide fragment 25-35 induced a 
decrease in PDIA3 protein but not in mRNA levels. We demonstrated that 
this decrease was not a consequence of ER stress, since we proved that this 
specific fragment of the amyloid β peptide did not cause activation of the 
unfolded protein response. We also proved that this decrease was not due to 
protein degradation through proteasome. Moreover, we observed a 
delocalization of PDIA3 toward the plasma membrane following Aβ 
treatment. Considering our data and since evidences about PDIA3 
extracellular presence can be found in the literature [Hirano et al., 1995; 
Erickson et al., 2005], we hypothesized that PDIA3 can be secreted under Aβ 
treatment. In this study we showed that PDIA3 is secreted by SH-SY5Y, with 
a significant increase after 1 hour of Aβ25-35 treatment. We also observed 
that PDIA3 secretion seemed not to be dependent on the classical secretion 
pathway Golgi-mediated. An explanation for this observation could be that 
PDIA3 is released from the cell within exosomes. This is not totally unlikely 
since Marimpietri et al. found PDIA3 in exosomes coming from a 
neuroblastoma cell line [Marimpietri et al., 2013]. Moreover PDIA3 is 
present in the ExoCarta Database as an exosome-associated protein. From 
data presented in this work, our hypothesis is that β-amyloid peptide induces 
a PDIA3 delocalization and secretion in the extracellular fluid as a possible 
defence mechanism carried out by the cell to counteract the toxic action of 
Aβ. Considering the work of Erickson et al., it could be that PDIA3 pursues 
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this aim through direct binding to amyloid β peptide in order to prevent its 
aggregation and keep it in solution. 
In the last part of my PhD, I focused my attention on ER stress and Unfolded 
Protein Response, in particular on one of its sensors, IRE1. The main focus 
was to study IRE1 activities, with special regard to the involvement of IRE1 
domains in its activation. We were also interested in how IRE1 clusters are 
related to its activities and how phosphorylation regulates them. In this study 
we observed that, in order to have activation of the RNase domain of IRE1 
and clustering, a functional luminal domain is required. Interestingly we 
found out that if the RNase domain of IRE1 is somehow inhibited, with a 
mutation or using a chemical inhibitor, IRE1 persists in clusters in the ER 
membrane. This means that IRE1 clustering initiation does not require the 
endoribonuclease activity of IRE1. Moreover this led us to hypothesize that 
IRE1 clustering can be related to other activities, such as RIDD or activation 
of the JNK pathway. Another interesting finding in this study was that a 
stimulus coming from the cytosol induces XBP1 mRNA splicing but not 
IRE1 clustering. Indeed, the flavonoid luteolin, through direct binding to the 
interphase between the kinase and endoribonuclease domains, triggers the 
splicing of XBP1 mRNA but it does not cause IRE1 redistribution in clusters 
in the ER membrane. This could be explained by the finding that luteolin 
induces a different degree in IRE1 phosphorylation if compared with the one 
induced by a common ER stress activator, such as thapsigargin. Our 
hypothesis is that luteolin induces phosphorylation only in the activation 
loop, which is sufficient to have XBP1 splicing, as proved by Prischi et al 
[Prischi et al., 2014], but in order to have IRE1 clustering, phosphorylation in 
additional residues is required. More studies are needed to confirm our 
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hypothesis and, more importantly, the next step will be to investigate the 
other IRE1 activities, RIDD and JNK-pathway activation, in order to relate 
every single IRE1 activity to its dimeric or oligomeric state. Moreover we 
want to better understand how the phosphorylation state of IRE1 affects its 
activities. Last, during the course of this study on IRE1, we discovered by 
chance a new IRE1 mutant, L827P, which has proven to be also an inhibitor 
of this enzyme. We are now interested in better characterizing the mechanism 
of action of this mutant with the intent to develop, in the future, small 
peptides that can inhibit IRE1 activity. Since it has been proved that IRE1 is 
involved in different pathologies, such as multiple myeloma, it can be used as 
a valid and promising pharmacological target. 
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